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r 1Venous disease is among the most common medical conditions to affect mankind; 
approximately 1-3% of the population of the Western world is estimated to have severe 
venous problems at some point in their lives1. Clinical manifestations range from 
asymptomatic varicose veins to venous ulceration. Varicose veins are the most common 
manifestation of CVI. Varicose veins have incompetent valves causing increased venous 
pressure which may lead to progressive vessel dilatation and tortuosity, skin changes 
and sometimes to ulceration. Venous disease is often the cause of discomfort, pain, loss 
of working days, and deterioration of health-related quality of life2,3. The treatment of 
symptomatic varicose veins imposes a high burden on health care budgets. In European 
countries venous disease consumes 1-2% of the health care budgets4.
For many years surgical treatment was the gold standard in treating varicose veins. 
Since the introduction of ultrasound examination in the early 1980s in patients suffering 
from varicose veins a better understanding has been gained concerning the underlying 
pathology of the clinical presentation in patients with venous disorders. For the physician 
it became possible to visualize the pathologic flow in the venous system and subsequently 
treatments could become minimally invasive, as they could now be performed intraluminally 
under ultrasound guidance. These therapies have quickly gained popularity and are used 
with increasing frequency including chemical and thermal ablation of the treated vessel. 
Chemical ablation is performed by using ultrasound guided foam sclerotherapy (UFGS), and 
thermal ablation by endovenous laser ablation (EVLA) and radiofrequency ablation (rFA). 
These treatment options have in common that they aim at obliterating veins with reflux. 
Nowadays minimally invasive techniques are favoured by both physicians and patients 
and replace surgical methods. The rapid development towards frequent use of these 
alternative treatments of varicose veins warrants evaluation of efficacy, safety and costs 
when compared with surgery. 
Epidemiology
The term chronic venous insufficiency (CVI) describes a medical condition in which venous 
hypertension affects the venous system of the lower limbs causing various symptoms 
including pain, swelling, oedema, skin changes, and ulcerations5. CVI represents the full 
spectrum of manifestations of chronic venous disease, but the term CVI is frequently used 
to exclude uncomplicated varicose veins. Although numerous epidemiological studies have 
been conducted it is difficult to determine the exact prevalence of chronic venous disease. 
Prevalence depends on the distribution of risk factors in the population including female 
gender, obesity, older age, pregnancy and deep venous thrombosis6. A cross sectional 
survey in Edinburgh also known as the Edinburgh vein study showed that the prevalence 
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of varicosis of the great or small saphenous vein was 40% in men and 32% in women and 
increases with age7.
The clinical manifestations of varicose veins vary broadly from relatively mild disease to 
more advanced skin changes and ulceration. In more than 60% of the population patients 
have mild venous disease, with no clinical signs at all or only the presence of teleangiectatic 
or reticular veins. Skin changes caused by venous disease, including venous ulcers, are 
found  in less than 10% and the prevalence for healed ulcers ranges from 0.6%-1.4% and 
is estimated to be about 0.5% for active ulcers7-10. The overall prognosis of venous ulcers 
is poor, more than 50% of venous ulcers require prolonged therapy for more than a year11. 
The total costs of this end stage of venous disease covers 1% of the total annual health care 
budget in Western European countries12. 
The rate of progression from uncomplicated varicose veins into complicated venous 
pathology accompanied by skin changes and ulceration remains poorly defined13.  The 
most reliable data on the natural course probably come from the population based Bonn 
Vein Study II in which an incidence of CVI progression from C1-C2 to C3-C6 of 2% per year 
within 6 years was reported14.
Pathophysiology
It seems that the basic pathophysiology of venous disorders have already been fairly 
understood by the ancients. A statement of Hippocrates was: “it was better not to stand 
in the case of an ulcer on the leg”15. The veins of the lower extremity are divided into the 
superficial and deep venous system connected by a series of perforator veins.  The two major 
superficial veins are small saphenous vein (SSV) and the great saphenous vein (GSV) (see 
Figure 1). The deep venous system is located underneath the muscular fascia and functions 
as collecting system for the venous outflow of the extremities. The superficial veins are 
connected to the deep venous system by a number of perforating veins in the thigh. Bicuspid 
valves and muscle pumps in the venous system ensure that blood flows in the direction of 
the heart, preventing the return of blood toward the feet in upright position16.  Failure of 
the valves results in pathological retrograde venous flow (reflux) and venous hypertension.
In the upright position and in the absence of muscle contraction venous hydrostatic 
pressure measured on the dorsum of the foot ranges from 90-120mmHg, depending on the 
individual’s height17. In the normal limb during ambulatory calf contractions mean venous 
pressure is reduced to 22mmHg18. In patients with CVI this pressure will not further decrease 
than 60-70mmHg. This venous hypertension can be caused by valvular incompetence of 
the axial deep or superficial veins, perforator valve incompetence, venous obstruction or a 
combination of these factors. 
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Saphenofemoral junction
Great saphenous vein
Deep femoral vein
Femoral vein
Popliteal vein
Small saphenous vein
Great saphenous vein
Figure 1. venous anatomy of lower extremities
Venous hypertension results in micro circulatory hemodynamic disturbances eventually 
leading to skin changes such as pigmentations, lipodermatosclerosis, atrophie blanche 
and venous ulcers19,20. Until now few studies have been performed on the clinical and 
haemodynamic effects of abolishing reflux on venous hypertension. In theory the abolishing 
of reflux should improve ulcer healing and prevent the progression of CVI. However there 
are no relevant studies that demonstrate a lessening effect of compression or surgical/
endovenous interventions on the progression of CVI13. There is evidence that abolishing 
reflux does not increase the healing rate of venous ulcers but decreases significantly the risk 
of ulcer recurrence21.
Clinical signs and symptoms
CVI of the lower limbs is characterized by symptoms and/or signs produced by venous 
hypertension as a result of structural or functional abnormalities of veins. Symptoms 
may include heaviness, leg-tiredness, cramps, aching, itching, restless leg syndrome and 
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swelling in the leg. Clinical signs of CVI may include teleangiectasia, reticular or varicose 
veins, edema and skin changes such as pigmentation, lipodermatosclerosis, eczema and 
ulceration (see Figure 2).
None of the venous symptoms are pathognomic for varicose veins and the relation between 
CVI signs and symptoms is not very strong. In large population based studies similar 
symptoms have been noted in participants without varicose veins22,23.
Figure 2. Clinical characteristics of chronic venous disease. A. Teleangiectases. B. reticular veins. C. Varicose veins. D. 
Edema. E. Lipodermatosclerosis and hyperpigmentation. F. Ulceration
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Since 1994 the CEAP classification is widely used in practice and scientific settings and is 
the gold standard to classify stages of venous diseases. This classification combines the 
manifestation of different clinical stages and underlying aetiology and pathology. In 2004, 
the basic CEAP classification has been revised (Table 1). However, its components have been 
recognized to be relatively incapable for monitoring changes in venous disease severity24.
Table 1. CEAP classification of chronic venous disease
Clinical classification
C0 No visible or palpable signs of venous disease
C1 Teleangiectases or reticular veins
C2 Varicose veins
C3 Edema
C4a Pigmentation and/or eczema
C4b Lipodermatosclerosis and/or atrophie blanche
C5 Healed venous ulcer
C6 Active venous ulcer
S Symptomatic, including ache, pain, tightness, skin irritation, heaviness, muscle cramps, as 
well as other complaints attributable to venous dysfunction
A Asymptomatic
Etiologic classification
Ec Congenital
Ep Primary
Es Secondary (postthrombotic)
En No venous etiology identified
Anatomic classification
As Superficial veins
Ap Perforator veins
Ad Deep veins
An No venous location identified
Pathophysiologic classification
Pr reflux
Po obstruction
Pr,o reflux and obstruction
Pn No venous pathophysiology identifiable
Advanced CEAP: Same as basic CEAP, with addition that any of 18 named venous segments can be used as locators 
for venous pathology.
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Diagnostic evaluation
Many of the signs and symptoms of CVI can be detected by physical examination, which 
still plays an important role in diagnosis. However it does not provide information about 
the anatomic extent of disease involving the deep and superficial venous systems. 
Duplex ultrasound is the test of choice for evaluation of varicose veins as it is safe, non-
invasive, cost-effective, and reliable. It enables distinction between congenital, primary, 
and secondary causes of CVD in the majority of cases6. The optimal position to perform 
duplex ultrasonography is a standing position where both reflux and obstruction can be 
evaluated in the deep, superficial and perforating veins. reflux can be elicited in two ways. 
With the Valsava method the intra-abdominal pressure is increased and in case of valvular 
incompetence, this may lead to reversal flow. The other way is to give manual compression 
distal to the point of examination, resulting in an initial increase of flow in the vein as the 
blood is pushed in the normal direction of flow. If the pressure is released, the blood flow 
reverses momentarily. In case of incompetent valves the blood continues to flow in reverse 
direction. The duration of reflux is known as the reflux time. A reflux time of >0.5s is being 
used to diagnose the presence of reflux.
Development of treatment
As early as the first century AD, a famous roman encyclopaedist, Aurelius Cornelius Celsus, 
used avulsion with a hook or a touch of a cautery to treat varicose veins25. In Byzantine times 
a Greek surgeon (607-690) recognized that ligation and removal of the great saphenous 
vein was important26. A first attempt to sclerotherapy, was already made in 1864 by the 
Frenchman Pravaz27. This method causes thrombus formation by injecting a sclerosant. In the 
early twentieth century, stripping of the saphenous veins was added to proximal ligation of 
the saphenofemoral junction. After development of several strippers in 1907 the “Babcock” 
stripper was introduced, a flexible internal stripper28. This stripper can be regarded as the 
prototype of all strippers that are currently in use. Following these early years attempts at 
devising a suitable stripping technique the pendulum swung back to sclerotherapy. In the 
1930s it even became the treatment of choice, the used sclerosant was sodium morrhuate29. 
After the 50s surgery gained more interest caused by publications which were nearly all in 
favour of the stripping technique30,31. For decades a high ligation of the saphenofemoral 
junction (SFJ) and short stripping of the GSV was the standard procedure for treating GSV 
reflux and is till today the gold standard. Studies on long-term results of surgery indicated 
recurrence rates of between 21% and 26% after 3 years and 60% after 34 years32-34. recurrence 
rates after GSV stripping are usually caused by neovasularization at the saphenofemoral 
junction (SFJ) stimulated by surgical dissection in this area35. Despite the good results of 
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a day case procedure under general or epidural anesthesia.There is a risk of  temporary 
or sometimes permanent cutaneous nerve injury after stripping which occurs in 5-7% of 
cases36. other complications may occur such as groin infection, haematoma and post-
operative pain37. Another disadvantage of surgery is the post-operative downtime, most 
patients are advised to resume their daily activities after 1 week which can be associated 
with considerable inconvenience and indirect health care costs38. 
Because of these disadvantages of surgery and the introduction of duplex ultrasound in 
the 80’s minimally invasive techniques have gained popularity and are used with increasing 
frequency. Ultrasound guided foamsclerotherapy (UGFS), radiofrequency ablation (rFA) 
and endovenous laser ablation (EVLA) are such minimally invasive techniques. In non-
randomized studies these techniques were reported to be successful in 69%-93% of 
patients at two years after treatment39-41. An advantage is that no general anaesthesia  or 
hospital stay is needed. 
UGFS sclerotherapy with foam is a novel further development of traditional sclerotherapy. 
Foam is a variant of liquid sclerotherapy in which the liquid-air mixture (foam) is injected in 
varicose veins under ultrasound guidance. orbach already made an attempt in 1940 with 
his air-block technique to displace the blood column to intensify the contact between the 
sclerosant and endothelium42. In 1995 Cabrera produced microfoam and reported about 
the clinical effectiveness in a series of 500 patients with larger varicose veins43.This is a 
variant of liquid sclerotherapy in which the liquid-air mixture (foam) is injected in varicose 
veins under ultrasound guidance. Compared with liquid sclerotherapy, UGFS is much more 
effective44,45. 
A major advantage of UGFS is that this technique is easy to perform and easy to learn. which 
makes it an accessible treatment modality for a large group of specialists involved in the 
treatment of varicose vein. This development of an easy-to-use and accessible technique to 
treat varicose veins instigated the need for comparison of foam sclerotherapy with surgery 
in a non-inferiority randomized controlled trial. In exchange for certain advantages, such 
as fewer side effects, more convenience and less healthcare costs as a society we may be 
willing to accept some loss in effectiveness, but it is necessary to make sure, that such a loss 
does not exceed a predefined margin.
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Aims of the thesis
This thesis will focus on UGFS as treatment modality for patients with varicose veins. The 
main objective was to evaluate effectiveness and healthcare costs in the treatment of the 
incompetent GSV. Secondary objectives were to explore safety in terms of the effect of 
foam injection on coagulability of blood and to identify predictors of treatment success 
after UGFS.
Outline of the thesis
Chapter 2 describes a Dutch consensus  for the physician  who is performing UGFS 
treatments. This consensus was written to achieve standardization of the treatment. A 
consensus meeting was held by experts. Based on their clinical experiences and a literature 
study a Dutch consensus was drawn up. 
Chapter 3 reports the results of a large multi-centre randomised non-inferiority trial 
comparing effectiveness and health care costs of surgery versus UGFS in the treatment of 
primary greater saphenous vein incompetence with a follow-up period of 2 years
Chapter 4 evaluates whether and which leg symptoms commonly attributed to a venous 
cause are characteristic for patients with chronic venous insufficiency (CVI). The VEINES-
Sym part of the VEINES-QoL/Sym questionnaire was used to evaluate the frequency of nine 
venous symptoms reported by CVI patients. These frequencies were compared to those 
reported by patients with other diseases of the lower legs, such as  arthrosis, peripheral 
arterial disease and spinal disc herniation. 
Chapter 5 describes a case report of a patient with a superficial thrombophlebitis and deep 
venous thrombosis after UGFS.   
Chapter 6 presents the results of a study on the in vivo effects of UGFS on blood coagulability. 
Changes from baseline in parameters that measure thrombin generation were assessed in 
patients who were treated with foam sclerotherapy. 
Finally, the aim of chapter 7 was to identify predictors of treatment success after UGFS. 
Such predictors can be used for selection of patients who are most likely to benefit from 
treatment with this modality
Chapter 8 provides a general discussion about the findings of this thesis.
Chapter 9 provides a summary of this thesis.
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Abstract
Foam sclerotherapy is increasingly being used to treat truncal varices, in view of its minimally 
invasive nature and the high success rate in terms of occlusion of varicose veins treated 
with this technique. To achieve standardization of the treatment, a consensus meeting 
was organized with Dutch experts. Based on their clinical experiences and literature data, 
the Dutch consensus statement presented here was drawn up. This consensus statement 
provides a guideline for the treatment of truncal varices with foam sclerotherapy and an 
overview of this new technique for specialists as well as general practitioners.
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Introduction
Chronic venous insufficiency (CVI) is characterized by various types of varices, some with 
associated skin abnormalities, which may in some cases even lead to venous ulcers.1 Varicose 
veins represent a burden to a large proportion of the population, with incidences of up to 
50%, rising with age.2 one in 10 of the affected persons reports varices-related symptoms 
that require treatment. Symptoms include a feeling of heaviness and fatigue in the legs, 
spasms, restless legs and venous claudication. The treatment consists of elimination of the 
underlying venous hypertension, which is often caused by truncal varices.
The gold standard for the treatment of primary truncal varices has always been surgical 
intervention. A new therapeutic option for truncal varices is foam sclerotherapy, a form of 
ultrasound guided sclerotherapy in which the sclerosant is mixed with air to create a foam.3 
In the Netherlands, foam sclerotherapy is applied by surgeons, dermatologists and 
radiologists. Compared to surgical interventions, the treatment is minimally invasive, 
patient-friendly and cost-effective.4 It is a suitable treatment for truncal varices, recurrent 
varices after surgery, teleangiectases/reticular veins and perforating vein varices, and is also 
used in some clinics for venous malformations and pelvic varices.3 More and more Dutch 
clinics have adopted foam sclerotherapy as a treatment for varicose veins, sometimes as an 
alternative to surgical intervention. There is, however, no standardized management policy 
for ultrasound-guided sclerotherapy in practice in the Netherlands. A consensus meeting 
was therefore held with experts in the field of ultrasound-guided foam sclerotherapy 
(vascular surgeons, radiologists and dermatologists) to draw up a Dutch consensus 
statement on the treatment of truncal varices, based on literature data (from PubMed) and 
the experts’ own experiences. This consensus statement can be used as a practice guideline. 
Indications
Ultrasound-guided foam sclerotherapy can be used for a variety of varices, ranging from 
reticular veins to truncal varices.5 This consensus statement only relates to the treatment 
of truncal varices, which is the most common indication. A few rare indications like 
venous malformations can also be treated with foam sclerotherapy, but require referral to 
specialized centres. 
Preparing the foam 
In the Netherlands, the foam is prepared by mixing the sclerosant polidocanol with air.5,6 
After intravenous administration, it causes destruction of the endothelial cells, which leads 
to thrombus formation and eventually to a fibrotic cord.7 Foam is prepared using the Tessari 
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method,8 which involves two 5 cc syringes being connected by a luer lock or three-way 
stopcock and being moved from side to side to side (Figure1) .
(a) sclerosant:air ratio
The foam is prepared using 1 mL of sclerosant to 3 or 4 mL of air (1:4 or 1:5 ratio).9 More air 
leads to a smaller foam bubble, causing a more viscous foam. This results in greater effect 
of the blood column displacement and a longer contact with the endothelium.10 A large 
majority of the experts in the consensus meeting reported using a 1:4 liquid:air ratio, but 
the meeting decided to adopt the 1:5 ratio in the consensus statement in view of the above-
mentioned advantages. No studies have been published in which various liquid:air ratios 
were compared. The 1:5 ratio (1 part liquid to 4 parts air) has been included in the consensus 
statement as the standard recommendation.
(b) Concentration-percentage of polidocanol
Polidocanol percentages ranging from 1% to 3% are being used for the treatment of 
truncal varices. Two recent studies have compared the efficacy of 1% polidocanol and 3% 
polidocanol in the treatment of truncal varices of the great saphenous vein; they found 
no significant difference in efficacy.11,12 Ceulen et al. compared the two groups in terms of 
side-effects (thrombophlebitis, hyperpigmentation), and found that thrombophlebitis and 
hyperpigmentation were more frequently seen in the polidocanol 3% group. 
These findings tie in with the clinical experiences reported by the experts attending the 
consensus meeting, a large majority of whom use polidocanol 1% foam. Both 1% and 3% 
polidocanol foam to treat truncal varices cause effective occlusion of the truncal varices. The 
meeting decided to include polidocanol 1% as the standard recommendation in the consensus 
statement, as this produces fewer side-effects like hyperpigmentation and phlebitis. 
Figure 1:.Tessari method
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Treatment
This section describes the practical details of administering foam sclerotherapy. The 
Nederlands Tijdschrift voor Geneeskunde journal website features a video of the treatment.
(a) Puncturing the vein
The course of the vein (great / small saphenous vein) is marked out with the patient standing 
up, using duplex ultrasound guidance. With the patient in supine position, the vessel is 
punctured using a 21-G needle or an 18-G venflon. Using a venflon offers advantages to the 
less experienced physician, such as checking the intravascular placement of the needle and 
a reduced risk of perforating the vein. Injection is stopped when the foam has progressed 
to within a few centimetres from the junction. 
(b) Where should the vein be punctured?
The great saphenous vein is usually punctured just above the knee, where the skin is strong 
and the varix is located superficially. If a different puncture site is chosen, this should be 
located at least 10 cm below the junction.9 
All experts at the consensus meeting reported that they punctured the small saphenous 
vein as distally as possible.
The consensus recommendation is thus to puncture the great saphenous vein just above 
the knee and the small saphenous vein as distally as possible, observing a minimum 
distance of 10 cm below the junction. 
Figure 2. Puncturing the vein under duplex guidance
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(c) Volume injected per treatment
Literature reports show that different volumes of foam are being injected per treatment, 
ranging from 6 mL to a maximum of 10 mL.9,13  The Dutch specialists taking part in the 
consensus meeting also used different volumes per treatment, ranging from 2 to 10 mL 
for the great saphenous vein and from 1 to 4 mL for the small saphenous vein. The volume 
required can be minimized by waiting for vascular spasm to occur during the slow injection 
procedure.13  The vascular spasm is also an indication that the treatment has been successful.
The consensus statement recommends a maximum volume per treatment of 10 mL:
Great saphenous vein: 2–10 mL
Small saphenous vein: 1–5 mL
Slow injection is preferred. The occurrence of a vascular spasm in the treated segment of the 
vein during the treatment signals the completion of the injection procedure.
Aftercare
Compression therapy
Doctors in the Netherlands as well as other countries generally apply compression therapy 
for about 4 to 6 weeks.14-16 A few studies have reported not using compression and still 
achieving effective occlusion of the vein.12 The consensus meeting preliminarily agreed 
on recommending 4 weeks of compression bandaging by means of a class II compression 
stocking, until new research has found more evidence that additional compression therapy 
offers no added value. Most of the specialists in the consensus group would also place a 
foampad or cotton wool bandage on the treated varix for 1 week, to add further pressure. 
Four weeks of compression therapy with a pelotte for additional local pressure in the first 
weeks was considered sufficient.
Contraindications
The use of foam sclerotherapy is subject to the same contraindications as fluid sclerotherapy 
(Table 1).
Table 1.  Contraindications for sclerotherapy
Allergic to the sclerosant
E-A index < 0.8
occlusion of deep or superficial venous system
Pregnancy
Poor general physical condition
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Conclusion
Foam sclerotherapy is an effective and minimally invasive intervention, offering effective 
treatment of truncal varices. The advantage of this treatment is that it does not require any 
anaesthesia and that patients can generally resume their normal activities soon. It is our 
expectation that foam sclerotherapy will become a much-used treatment for truncal varices 
in the future.
our intention in producing this consensus statement (Table 2) was to inform interested 
general practitioners of the existence of this minimally invasive technique and to offer 
specialists guidelines for the treatment of truncal varices by foam sclerotherapy. Standardized 
application of the technique may optimize the results achieved. 
Table 2. Summary of foam sclerotherapy consensus statement
Summary of foam sclerotherapy consensus
1 Foam sclerotherapy is an effective treatment for varices, especially truncal varices.
2 Foam should be prepared by the Tessari method.
3 Foam should be prepared using 1 ml sclerosant to 4 ml air.
4 Polidocanol 1% should be used for the treatment of truncal varices.
5 Puncturing the vein using a venflon is recommended.
6 The great saphenous vein should be punctured just above the knee, the small saphenous 
vein as distally as possible.
7 A minimal distance of 10 cm should be maintained between the injection site and the 
junction.
8 A maximum of 10 mL foam should be used per treatment.
9 A slow injection procedure should be used.
10 Treatment should be followed by 4 weeks of compression therapy.
11 Contraindications are the same as those for fluid sclerotherapy.
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Abstract
Background: New minimally invasive treatment modalities, such as ultrasound-guided foam 
sclerotherapy (UGFS), are becoming more popular. In a multicentre randomized controlled 
non-inferiority trial, the effectiveness and costs of UGFS and surgery for treatment of the 
incompetent great saphenous vein (GSV) were compared.
Methods: Patients with primary great saphenous varicose veins were assigned randomly to 
either UGFS or surgical stripping with high ligation. recurrence, defined as reflux combined 
with venous symptoms, was determined on colour duplex scans at baseline, 3 months, 1 
year and 2 years after initial treatment. Secondary outcomes were presence of recurrent 
reflux (irrespective of symptoms), reduction of symptoms, health-related quality of life (EQ-
5D™), adverse events and direct hospital costs.
Results: Two hundred and thirty patients were treated by UGFS and 200 underwent GSV 
stripping. The 2-year probability of recurrence was similar in the UGFS and surgery groups: 
11.3 per cent (24 of 213) and 9.0 per cent (16 of 177) respectively (P=0.407). At 2 years, reflux 
irrespective of venous symptoms was significantly more frequent in the UGFS group (35.0 
per cent) than in the surgery group (21.0 per cent) (P=0.003). Mean(s.d.) hospital costs per 
patient over 2 years were €774(344) per patient for UGFS and €1824(141) for stripping.
Conclusion: At 2-year follow-up, UGFS was not inferior to surgery when reflux associated 
with venous symptoms was the clinical outcome of interest. UGFS has the potential to be a 
cost-effective approach to a common health problem. registration numbers: NCT01103258 
(http://www.clinicaltrials.gov) and NTr654 (http://www.trialregister.nl).
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Introduction
Lower-extremity venous insufficiency is a common health problem in Western countries, 
and its prevalence increases with age. Epidemiological studies show that a quarter of 
the adult population have varicose veins1. This condition is often associated with great 
saphenous vein (GSV) reflux1–3. The disease has a substantial impact on quality of life, as 
well as on the resources and budgets of healthcare systems2. For many years, the standard 
treatment was surgical stripping of the GSV. research comparing liquid sclerotherapy and 
surgery for the treatment of GSV incompetence showed that surgery was more effective3,4. 
Long-term results of surgery indicated recurrence rates of between 21 and 26 per cent 
after 3 years of follow-up and 60 per cent after 34 years5–7. However, in recent years there 
has been an increased demand for minimally invasive and less expensive procedures such 
as ultrasound-guided foam sclerotherapy (UGFS), endovenous laser ablation (EVLA) and 
radiofrequency ablation (rFA)8. UGFS is a variant of liquid sclerotherapy, in which the liquid–
air mixture (foam) is injected into varicose veins under ultrasound guidance. Compared 
with liquid sclerotherapy, UGFS is more effective9,10. UGFS has a reported success rate of 
75–85 per cent after 1 year and 69 per cent after 2 years of follow-up11–13. Advantages of 
this treatment are that it is less invasive, reduces healthcare costs, and is associated with a 
shorter recovery time than surgery14–16, making UGFS an attractive alternative to surgery for 
the treatment of varicose veins.
The aim of the present multicentre randomized clinical trial was to compare the effectiveness 
and hospital costs of UGFS with those of surgery in treatment of the incompetent GSV. 
Although success rates after one UGFS session may be lower than after surgery, UGFS can 
be a cost-effective alternative to surgery because of the easy and relatively low cost of 
retreatment.
Methods
Consecutive patients referred for treatment of symptomatic varicose veins by general 
practitioners were recruited at the outpatient dermatology and surgery departments of 
three hospitals in the Netherlands: Maastricht University Medical Centre, Atrium Medical 
Centre Heerlen and Laurentius Hospital roermond.
Screening assessments included medical history, clinical examination and duplex imaging. 
Patients with a primary GSV incompetence were eligible; inclusion criteria were the 
presence of one or more venous symptoms, in combination with incompetence of the 
saphenofemoral junction and GSV (measured over a distance of at least 20 cm in the upper 
leg) and a reflux time of more than 0.5 s, and a normal deep venous system on duplex 
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imaging. Patients with an incompetent deep venous system, signs of a previous deep 
venous thrombosis on duplex imaging, an active ulcer or a contraindication to the use of 
polidocanol were excluded.
The trial was approved by the medical ethics committee of Maastricht University Medical 
Centre. All patients provided written informed consent before participating in the study, 
according to the principles of the Declaration of Helsinki.
Randomization
Eligible patients with primary incompetence of the GSV were included and assigned 
randomly to UGFS or surgery using a computer-generated randomization scheme with 
random permuted blocks of eight.
Outcome measures
The primary outcome measure of this study was the cumulative probability of recurrent 
varicose veins 2 years after treatment. recurrence of varicose veins was defined as the 
presence of one or more venous symptoms such as pain, cramps, restless legs and a 
tired/heavy feeling in the treated leg, in combination with the presence of reflux longer 
than 0.5 s. This primary outcome measure was chosen for pragmatic reasons, because in 
clinical practice only patients with both venous reflux and symptoms are candidates for 
retreatment. recurrent reflux was defined as reflux for more than 2 cm in length in the 
treated vein segment (proximal GSV) as measured by colour flow Doppler ultrasonography. 
Duplex findings of the treated proximal GSV were categorized as: 1 absence of reflux; 2, 
reflux; 3, occlusion; 4, partial occlusion with reflux; 5, absence of vein. Patients in categories 
2 and 4 were considered to have reflux. Duplex findings in the distal GSV and other veins 
were also recorded.
Secondary outcomes were presence of recurrent reflux (irrespective of symptoms), 
reduction of symptoms, health-related quality of life (EQ-5D™; EuroQol Group, rotterdam, 
The Netherlands), adverse events and direct hospital costs.
outcomes were evaluated at baseline, 3 months, 1 year and 2 years after treatment. Patients 
were asked about the presence of venous complaints such as pain, cramps, tired/heavy 
feeling and restless legs. The frequency of symptoms was classified into four categories: 
1, absent; 2, occasional; 3, frequent; 4, continuous. Patients were also asked to indicate 
whether the treatment met their expectations in terms of aesthetic and functional outcome 
(reduced symptoms), with the following answer options: 1, not meeting expectations; 2, 
partially meeting expectations; 3, fully meeting expectations. A Clinical Etiologic Anatomic 
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Pathophysiologic (CEAP) classification was performed; all varicose veins were mapped and 
a Venous Clinical Severity Score (VCSS) was assigned by the research physician.
Patients’ health-related quality of life was measured by means of the EQ-5D™. EQ-5D™ 
consists of five dimensions (mobility, self-care, usual activities, pain and mood), each of 
which is rated at three levels (no problems, some problems, severe problems), yielding 243 
potential combinations of health states. Each health state is associated with a utility score by 
means of an additive function derived from the Dutch general population17(1). Furthermore, 
EQ-5D™ consists of a visual analogue scale (VAS) on which patients can rate their health 
state from worst possible (0) to best possible (100).
Colour duplex imaging
Duplex examination was performed at baseline, 3 months, 1 year and 2 years after treatment 
by an independent ultrasound technician using a colour duplex scanner (MyLab25™; Esaote 
Benelux, Maastricht, The Netherlands) with a 10-MHz transducer to detect venous reflux in 
the GSV and perform venous mapping of the entire deep and superficial venous system. 
Duration of reflux in the GSV was measured by colour-flow Doppler ultrasonography. 
Treated veins were screened for venous occlusion, flow and compressibility.
Ultrasound-guided foam sclerotherapy
The GSV was identified by duplex imaging in the standing position and marked from the 
groin following the path of reflux in the GSV. Sclerosing foam was prepared with the double-
syringe technique, applying a 1 : 4 ratio of sclerosant : air. one syringe was filled with 1 ml 
3 per cent polidocanol (Aethoxysklerol®; Kreussler Pharma, Wiesbaden, Germany) and the 
other syringe with 4 ml air. Patients were treated in supine position with an 18-Fr intravenous 
cannula (B. Braun, Melsungen, Germany), which was inserted just above the knee. The 
treatment was considered successful when the proximal GSV was completely filled with 
foam and maximal venospasm was achieved. The majority of patients received an injection 
of 5 ml or more; 48 patients received less than 5 ml. Elevation of the leg or compression 
of the saphenofemoral junction was not used. Compression was applied with a foam pad 
over the treated area and an antiembolism stocking (Brevet TX 10 mmHg; Mölnlycke Health 
Care Benelux, Breda, The Netherlands) for 1 week, day and night. A class II elastic stocking 
(Mediven® Plus 23 mmHg; Medi, Bayreuth, Germany) was prescribed during the day for 6 
weeks. After treatment, patients were instructed to walk for at least 30 min, after which they 
could resume their usual daily activities. If necessary, patients received additional treatment 
at the subsequent visits for other varicose veins with UGFS or phlebectomy.
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Surgery
The surgery was done as a day-case procedure under general or spinal anaesthesia. A groin 
incision was carried out and the saphenofemoral junction dissected. After ligating side 
branches of the GSV, the saphenofemoral junction was ligated and the GSV divided and 
stripped to just below the knee using a stripper (Multistrip™; Prodimed, Neuilly en Thelle, 
France). The incision in the groin was closed with 3-0 polyglactin 910 subcutaneously and 
with 4-0 poliglecaprone 25 intracutaneously. The decision to perform phlebectomies was 
left to the surgeon. The leg was bandaged from distal to proximal. After surgery, the patient 
was mobilized immediately. After 48 h, the bandages were replaced by a class II elastic 
stocking (Mediven Plus 23 mmHg) for 6 weeks. Patients were advised to resume their usual 
daily routine after 1 week.
Cost analysis
The cost analysis was performed from a hospital perspective with a 2-year time horizon. 
Data regarding resource use were obtained for each patient from case report forms. Cost 
data included costs of outpatient visits, study treatment (UGFS or stripping), retreatment, 
and complementary treatment of the GSV and other varicose veins during follow-up. Unit 
prices, comprising personnel, materials, capacity and overhead costs, were obtained from 
the finance department of Maastricht University Medical Centre. All prices were expressed 
in 2008 euros. Hospital costs over 2 years were calculated by multiplying resource use by 
cost price per unit of resource use. Costs occurring after 1 year were discounted.
Statistical analysis
The study was designed as a non-inferiority trial. Based on literature data, the 2-year 
probability of recurrent varicose veins after standard treatment by surgery was assumed as 
30 per cent. Power calculation showed that a total sample size of 460 patients was required 
to detect a 10 per cent difference in failure rate between surgery and UGFS with a power of 
80 per cent (one-sided type I error of 0.05).
Differences between treatment groups in the proportions of patients with a specific outcome 
at 3 months, 1 year and 2 years after treatment were tested for statistical significance 
using the χ2 test. Ninety-five per cent confidence intervals (c.i.) around the difference in 
proportions were calculated18. P<0.050 was considered to indicate statistical significance. 
only patients who underwent the allocated intervention were included in the analysis. All 
data were analysed with SPSS® version 16.0 (SPSS, Chicago, Illinois, USA) and Stata® version 
11.1 (SAS Institute, Cary, North Carolina, USA).
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Results
From october 2005 to December 2007, 530 patients were eligible for the study. Seventy 
patients were excluded and 55 with an incompetent GSV declined to participate, usually 
because they had a preference for one of the two treatments. Finally, 460 patients with 
primary incompetence of the GSV were randomized (Fig. 1). of the 233 patients assigned 
to UGFS, 230 were treated by this modality; three patients withdrew from the study after 
randomization. of the 227 patients assigned to surgery, 200 were treated and 27 withdrew 
from the study, 24 of whom declined surgical treatment.
Baseline data were available for 460 patients. According to the CEAP classification, assessed 
by the coordinating researcher, all patients had C2–C5EpAsPr disease. Complete follow-
up data for up to 2 years after treatment were obtained for 213 (92.6 per cent) of the 230 
patients in the UGFS group and for 177 (88.5 per cent) of the 200 patients having surgery 
(Fig. 1). Table 1 shows the baseline characteristics of the 460 enrolled participants, and of 
the 430 who underwent the assigned treatment. Baseline characteristics were similar in the 
two groups. VAS values at baseline were lacking for 50 (11.6 per cent) of the 430 treated 
patients owing to logistical problems.
Table 1. Baseline characteristics of randomized and treated patients assigned to ultrasound-guided foam 
sclerotherapy or surgery.
Randomized patients (n=460) Treated patients (n=430)
UGFS (n=233) Surgery (n=227) UGFS (n=230) Surgery (n=200)
Age (years)* 55.8(13.4) (27–87) 54.6(13.4) (24–86) 51.6(13.3) (22–83) 50.7(13.4) (20–81)
Sex ratio (F : M) 175 : 58 162 : 65 173 : 57 141 : 59
Clinical presentation†
C2 (varicose veins) 191 (82.0) 181 (79.7) 188 (81.7) 156 (78.0)
C3 (veins with oedema) 18 (7.7) 23 (10.1) 18 (7.8) 23 (11.5)
C4 (skin change) 19 (8.2) 17 (7.5) 19 (8.3) 15 (7.5)
C5 (healed ulcer) 5 (2.1) 6 (2.6) 5 (2.2) 6 (3.0)
GSV diameter (mm)*
Upper thigh 6.1(2.0) (2.3–15.4) 6.6(2.4) (2.2–18.6) 6.1(2.0) (2.3–15.4) 6.8(2.4) (2.2–18.6)
Mid thigh 5.5(1.8) (1.5–13.6) 5.8(2.0) (2.3–12.0) 5.5(1.8) (1.5–13.6) 5.9(2.0) (2.3–12.0)
Lower thigh 5.2(1.9) (1.2–12.8) 5.5(2.0) (1.4–15.0) 5.2(1.9) (1.2–12.8) 5.7(2.0) (1.4–15.0)
Duration of GSV reflux (s)* 2.4(1.6) (0.5–8.0) 2.5(1.7) (0.5–9.0) 2.4(1.6) (0.5–8.0) 2.6(1.9) (0.6–9.0)
Volume of foam (ml)* ??? – 5.4(2.0) (2–20) –
*  Values are mean(s.d.) (range); †values in parentheses are percentages. UGFS, ultrasound-guided foam sclerotherapy; 
GSV, great saphenous vein.
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Figure 1. CoNSorT diagram for the trial. UGFS, ultrasound-guided foam sclerotherapy
Two years after treatment the probability of recurrence in the UGFS group was 11.3 per 
cent (24 of 213), compared with 9.0 per cent (16 of 177) in the surgery group (P=0.407) 
(Fig. 2a). The difference in proportions was 2.3 (95 per cent c.i. -4.3 to 8.1) per cent. During 
follow-up, differences between the treatments emerged with respect to anatomical results 
(presence of reflux irrespective of venous complaints). Although there were no significant 
differences at 3 months and 1 year after treatment, the proportion of patients with reflux 
irrespective of venous symptoms 2 years after treatment was significantly higher following 
UGFS than for surgery: 35.0 and 21.0 per cent respectively, difference 14.0 (4.4 to 22.5) per 
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cent (P=0.003) (Fig. 2b). However, the percentage with reflux in the surgery group may have 
been underestimated, because in this group nine of ten patients with reflux at 1 year did 
not attend the final consultation at 2 years, compared with only one patient in the UGFS 
group. Assuming that recurrent varicosities in these patients were still present at 2 years, the 
proportion of patients with reflux would be 35.0 and 24.7 per cent in the UGFS and surgery 
group respectively: difference 10.3 (0.8 to 19.3) per cent (P=0.025).
reflux in the distal GSV below the knee at 2 years was present in 41.3 and 42.9 per cent 
respectively of patients in the UGFS and surgery groups (P=0.746)
of the 230 patients treated with foam sclerotherapy, 61 patients had additional treatment. 
Two patients had UGFS of the small saphenous vein (SSV) and 14 of a tributary of the 
Figure 2. Percentage  of patients with reﬂux a in combination with venous symptoms and b irrespective of venous 
symptoms at 3, 12 and 24 months of follow-up following ultrasound-guided foam sclerotherapy  (UGFS) or surgery. 
*P = 0•407 and †P = 0•003 versus UGFS  (χ2  test).
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GSV, 26 patients had phlebectomy of a tributary of the GSV and 19 had sclerotherapy of 
telangiectatic veins. In the surgery group, phlebectomy was done in 87 (43.5 per cent) of 
200 stripping procedures. At subsequent visits, 28 patients had an additional treatment; 
one patient had UGFS of the SSV, seven patients had phlebectomy of a tributary of the GSV, 
four were treated by foam sclerotherapy of a tributary and 16 patients had sclerotherapy for 
telangiectatic veins.
Symptom scores
At 2 years the mean change in the VCSS from baseline was similar in the two groups: −1.49 
in the UGFS group versus −1.75 in the surgery group (P=0.232). Change in health-related 
quality of life did not vary between groups. The mean change in the EQ-5D™ utility score 
(score at 2 years of follow-up minus score at baseline) was 0.064 and 0.061 in the UGFS and 
surgery groups respectively (P=0.889). The mean changes for the VAS scores were −0.36 in 
the UGFS and −1.8 in the surgery group (P=0.577). After 2 years, no significant differences 
in symptom relief were observed between treatment groups. The greatest impact of both 
treatments was observed on cramps and heavy or tired feeling, whereas pain and restless 
legs were less affected by treatment (Table 2). Complete satisfaction with the reduction of 
venous complaints was reported by 59.6 per cent of patients in the UGFS group and 66.1 
per cent of those having surgery (P=0.207).
Retreatment
of the 230 patients in the UGFS group, 190 (82.6 per cent) had only one treatment session. 
Forty patients had a repeat session with UGFS, five of whom had more than two sessions. Two 
patients in the surgery group had re-exploration of the groin. Eight patients were referred 
for UGFS by their surgeon because reoperation was technically difficult. In both treatment 
groups, some patients with recurrence were not retreated because they considered their 
symptoms not serious enough, or the surgeon recommended conservative treatment with 
elastic stockings.
Adverse events
Thrombophlebitis as an adverse event of UGFS occurred in 17 (7.4 per cent) of the 227 
patients (Table 3). Seven patients required non-steroidal anti-inflammatory drugs (diclofenac 
50 mg three times daily) and compression. After surgery, four patients developed a groin 
infection, two of which required surgical evacuation. Paraesthesia after surgery persisted 
in six patients, who experienced numbness in the upper or lower leg, although no severe 
nerve injuries were seen. Within 1 week after treatment, two patients in the UGFS group 
experienced a serious adverse event: one patient had a deep venous thrombosis and the 
other had a pulmonary embolus. Both patients were treated according to protocol with oral 
anticoagulant therapy.
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Table 2: Effect of ultrasound-guided foam sclerotherapy and surgery on venous symptoms and patient satisfaction 
of patients with aesthetic and functional outcomes at 3, 12 and 24 months
3 months 12 months 24 months
UGFS 
(n=217)
Surgery 
(n=176)
P*
UGFS 
(n=221)
Surgery 
(n=188)
P*
UGFS 
(n=213)
Surgery 
(n=177)
P*
Venous symptoms
Pain 0.792 0.833 0.340
More 12 (5.5) 10 (5.7) 20 (9.0) 14 (7.4) 14 (6.6) 6 (3.4)
Stable 111 (51.2) 84 (47.7) 109 (49.3) 93 (49.5) 104 (48.8) 86 (48.6)
Less 94 (43.3) 82 (46.6) 92 (41.6) 81 (43.1) 95 (44.6) 85 (48.0)
Tired/heavy feeling 0.273 0.287 0.454
More 8 (3.7) 2 (1.1) 5 (2.3) 9 (4.8) 6 (2.8) 5 (2.8)
Stable 71 (32.7) 61 (34.7) 85 (38.5) 64 (34.0) 74 (34.7) 51 (28.8)
Less 138 (63.6) 113 (64.2) 131 (59.3) 115 (61.2) 133 (62.4) 121 (68.4)
Cramps 0.641 0.748 0.364
More 9 (4.1) 6 (3.4) 10 (4.5) 9 (4.8) 8 (3.8) 8 (4.5)
Stable 79 (36.4) 72 (40.9) 84 (38.0) 78 (41.5) 79 (37.1) 77 (43.5)
Less 129 (59.4) 98 (55.7) 127 (57.5) 101 (53.7) 126 (59.2) 92 (52.0)
restless legs 0.525 0.867 0.865
More 27 (12.4) 16 (9.1) 34 (15.4) 26 (13.8) 29 (13.6) 21 (11.9)
Stable 153 (70.5) 126 (71.6) 150 (67.9) 132 (70.2) 145 (68.1) 124 (70.1)
Less 37 (17.1) 34 (19.3) 37 (16.7) 30 (16.0) 39 (18.3) 32 (18.1)
Patient satisfaction
Aesthetic 0.134 0.763 0.029
Not 
satisfied
39 (18.0) 19 (10.8) 33 (14.9) 32 (17.0) 31 (14.6) 23 (13.0)
reasonably 
satisfied
95 (43.8) 82 (46.6) 89 (40.3) 70 (37.2) 97 (45.5) 60 (33.9)
Fully 
satisfied
83 (38.2) 75 (42.6) 99 (44.8) 86 (45.7) 85 (39.9) 94 (53.1)
Functional 0.058 0.095 0.207
Not 
satisfied
20 (9.2) 15 (8.5) 22 (10.0) 28 (14.9) 17 (8.0) 17 (9.6)
reasonably 
satisfied
76 (35.0) 43 (24.4) 70 (31.7) 44 (23.4) 69 (32.4) 43 (24.3)
Fully 
satisfied
121 (55.8) 118 (67.0) 129 (58.4) 116 (61.7) 127 (59.6) 117 (66.1)
Values in parentheses are percentages. UGFS, ultrasound-guided foam sclerotherapy. *χ2 test.
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Costs
The cost analysis showed mean total hospital costs per patient of €774 for UGFS and €1824 
for surgery (Table 4). The difference was mainly due to the costs of treatment and preceding 
visits to outpatients, which totalled €343 per patient for UGFS and €1504 for surgery. Costs of 
retreatment and complications were slightly higher for UGFS. Although complications were 
recorded in the case report form, the consequences in terms of hospital resource use were 
not, so these costs were estimated. Thrombophlebitis was assumed to require two outpatient 
visits and 1 week of diclofenac treatment (€0.56 per day). Patients with a groin infection were 
assumed to visit the outpatient department two times (3 times for those needing surgical 
evacuation) and to require 1 week of flucloxacillin (€2.82 per day). The costs of deep venous 
thrombosis and pulmonary embolism were based on a paper by ten Cate-Hoek et al.19.
Discussion
The principal finding of this randomized clinical trial with a 2-year follow-up was that UGFS 
was not inferior to surgery when reflux associated with venous symptoms was considered 
the clinical outcome of interest. The combination of reflux and venous symptoms was chosen, 
because it reflected clinical practice, where patients are only treated if they have symptomatic 
varicose veins. If reflux alone was considered the outcome, patients in the surgery group 
were significantly advantaged. Hospital costs were considerably reduced, by about €1050 per 
patient, when UGFS was used for the treatment of great saphenous varicose veins.
Table 3. Complications and side-effects after treatment of the incompetent great saphenous vein with ultrasound-
guided foam sclerotherapy or surgery.
UGFS Surgery P*
Early complications (within 1 week) n=230 n=200
Groin infection 0 (0) 4 (2.0) 0.031
Haematoma 0 (0) 3 (1.5) 0.062
Paraesthesia 0 (0) 6 (3.0) 0.008
Pain at injection site 6 (2.6) 0 (0) 0.021
Thrombophlebitis 17 (7.4) 0 (0) < 0.001
Headache/migraine 3 (1.3) 0 (0) 0.105
Deep venous thrombosis 1 (0.4) 0 (0) 0.351
Pulmonary embolism 1 (0.4) 0 (0) 0.351
Late complications (at 2 years) n=213 n=177
Hyperpigmentation 12 (5.6) 2 (1.1) 0.017
Telangiectatic matting 6 (2.8) 2 (1.1) 0.242
Values in parentheses are percentages. UGFS, ultrasound-guided foam sclerotherapy. *χ2 test.
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Table 4. Hospital costs for patients treated by ultrasound-guided foam sclerotherapy or stripping.
Unit 
price (€)
UGFS (n=230) Surgery (n=200)
No. of patients 
using resource
Mean(s.d.) cost 
per patient (€)
No. of patients 
using resource
Mean(s.d.) cost 
per patient (€)
First visit at department of
Dermatology 98.41 230 98. 41(0.00) – –
Surgery 143.69 – – 200 143.69(0.00)
Anaesthetics 380.99 – – 200 380.99(0.00)
Initial treatment
UGFS 244.94 230 244.94(0.00) – –
Stripping 979.79 – – 200 979.79(0.00)
Follow-up after initial treatment (months)
3 98.41 217 92.85(22.78) 176 86.60(32.06)
12 98.41 221 94.56(19.12) 188 92.51(23.43)
24 98.41 213 91.14(25.80) 177 87.09(31.47)
retreatment
UGFS 244.94 43 52.18(117.35) 10 13.47(61.13)
Stripping 979.79 – – 2 9.80(97.75)
Follow-up 98.41 30 12.84(35.67) 6 2.95(16.83)
Complementary treatment
UGFS 244.94 16 17.03(66.50) 5 6.12(38.34)
Phlebectomy 228.89 26 26.00(78.84) 7 8.01(42.20)
Sclerotherapy 65.31 19 5.40(18.02) 16 5.22(18.93)
Complications
Deep venous 
thrombosis
1322.00 1 5.75(87.17) 0 –
Pulmonary 
embolism
4210.00 1 18.30(277.60) 0 –
Groin infection 378.97 0 – 4 7.58(53.19)
Thrombophlebitis 200.74 17 14.84(52.63) 0 –
Total 230 774.24(344.08) 200 1823.82(140.90)
Comparison with the literature regarding the effectiveness of UGFS and surgery is difficult 
because of differences in primary outcomes and follow-up. Two other randomized trials have 
compared UGFS with surgery13,22, but these had a limited follow-up of 1 year. The trial of 
rasmussen and colleagues13 showed efficacy for both treatments but the technical failure 
rate (defined as an open part of the treated vein segment greater than 10 cm in length) was 
higher after UGFS (16.3 per cent) than after surgery (4.8 per cent). The Varisolve trial of Wright 
and coworkers22 showed success rates of 68.2 per cent for UGFS and 87.2 per cent for surgery 
after 1 year; surgery was more effective, but UGFS caused less pain and patients resumed 
their daily routine more quickly.
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In the present study, side-effects such as hyperpigmentation and thrombophlebitis were 
the most common complications in the UGFS group. one deep venous thrombosis and one 
pulmonary embolism occurred in the UGFS group. Neither of these patients was at increased 
risk of thromboembolic events, nor did any sign of post-thrombotic syndrome such as deep 
venous occlusion or reflux develop during 2 years of follow-up. The rate of thromboembolic 
events in this study (0.4 per cent) corresponds to reported rates of between 0.02 and 1.25 per 
cent in other studies of UGFS23,24.
UGFS was substantially cheaper than surgery, explained mainly by the lower costs of 
treatment; UGFS does not require general anaesthesia and can therefore be applied as 
a simple outpatient procedure. It is acknowledged that real-world costs are probably 
confounded with study-induced costs, which is the case in many studies that apply an active 
follow-up scheme. This applies especially to the surgery group as, in routine practice, these 
patients have only one follow-up visit 10 days after surgery in the study hospitals. In the 
present study, follow-up visits were planned at 3, 12 and 24 months, and these visits may 
have induced costs (due to retreatment and complementary treatment) that in normal 
practice would not have been made. Nevertheless, even if all costs related to follow-up in 
the surgery group are excluded from the analysis, surgery remains more costly. In Western 
countries, the treatment of varicose veins imposes a considerable burden on the healthcare 
budgets25,26. In the Netherlands, €274 million a year is spent on the treatment of venous 
diseases, accounting for 6 per cent of total healthcare costs27. replacing surgery by UGFS 
would result in a cost reduction of more than €1000 per patient and could substantially lower 
the healthcare costs of varicose veins.
Minimally less invasive techniques such as UGFS and endothermal ablation techniques, 
for example EVLA and rFA, are becoming increasingly popular in the treatment of varicose 
veins. At the start of the present study, experience with the latter treatment modalities was 
still limited in the Netherlands, which was the reason to focus on comparison of surgery with 
UGFS. The results support the trend towards the use of minimally invasive techniques. An 
advantage of UGFS over endothermal ablation techniques is that tumescent anaesthesia is 
not required. Moreover, UGFS is easy to learn, making it an accessible treatment modality for 
a large group of practitioners such as dermatologists, surgeons and radiologists.
This study had some limitations. First, after randomization, 26 patients declined the 
treatment to which they had been randomized. The fact that 24 patients declined treatment 
in the surgery group versus two in the UGFS group could indicate that some patients had 
hoped to be assigned to UGFS. The withdrawal of these patients is unlikely to have affected 
the study results, because it did not affect the comparability of the two treatment groups. 
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Second, blinding was not feasible, because of the visible scars after surgical treatment and 
obliteration of the GSV after UGFS. However, outcomes were assessed objectively using 
colour duplex imaging by an analyst not involved in the study. The duplex technician was 
affiliated to neither the dermatology nor the surgery department. Third, loss to follow-up 
meant that the intended sample size of 460 patients was not achieved. However, with the 
actual numbers of 200 patients in the surgery group and 230 in the UGFS group, the post 
hoc power in this study would have been 92.6 per cent (α = 5 per cent) to detect a minimal 
clinically relevant increase in the risk of recurrence of 10 per cent or more after UGFS. Fourth, 
the number of patients having additional treatments was higher in the surgery group than 
for UGFS, because it is common practice to perform phlebectomies during a stripping 
procedure. This lack in comparability of co-interventions may have favoured surgery. Finally, 
this trial had a limited follow-up of 2 years. results showed that presence of reflux alone was 
observed significantly more often after treatment with UGFS. As the presence of reflux is a 
reliable predictor of symptoms of recurrent varicose veins developing in the future, longer 
follow-up is required to arrive at definite conclusions.
Acknowledgements
The authors thank Linda Spijker for collecting data on hospital costs and quality of life, and 
Monique de Laat for performing the duplex examinations. The study was funded by the 
Netherlands organisation for Health research and Development (ZonMw), which had no 
role in the study design, the collection, analysis, and interpretation of the data, or the writing 
of the report. The corresponding author had full access to all data in the study and had final 
responsibility to submit it for publication.
Conflict of Interest
Disclosure: The authors declare no conflict of interest.
 50 Chapter 3
References
 1. Wong JK, Duncan JL, Nichols DM. Whole-leg duplex mapping for varicose veins: observations on 
patterns of reflux in recurrent and primary legs, with clinical correlation. Eur J Vasc Endovasc Surg 2003; 
25: 267–275.
 2. Engelhorn CA, Engelhorn AL, Cassou MF, Salles-Cunha SX. Patterns of saphenous reflux in women with 
primary varicose veins. J Vasc Surg 2005; 41: 645–651.
 3. Evans CJ, Fowkes FG, ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in 
men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health 1999; 
53: 149–153.
 4. Eberhardt rT, raffetto JD. Chronic venous insufficiency. Circulation 2005; 111: 2398–2409.
 5. Hobbs JT. Surgery and sclerotherapy in the treatment of varicose veins. A random trial. Arch Surg 1974; 
109: 793–796.
 6. Lofgren KA, ribisi AP, Myers TT. An evaluation of stripping versus ligation for varicose veins. AMA Arch 
Surg 1958; 76: 310–316.
 7. van rij AM, Jiang P, Solomon C, Christie rA, Hill GB. recurrence after varicose vein surgery: a prospective 
long-term clinical study with duplex ultrasound scanning and air plethysmography. J Vasc Surg 2003; 38: 
935–943.
 8. Fischer r, Linde N, Duff C, Jeanneret C, Chandler JG, Seeber P. Late recurrent saphenofemoral junction 
reflux after ligation and stripping of the greater saphenous vein. J Vasc Surg 2001; 34: 236–240.
 9. Neglen P. Long saphenous stripping is favored in treating varicose veins. Dermatol Surg 2001; 27: 901–
902.
10. Kanwar A, Hansrani M, Lees T, Stansby G. Trends in varicose vein therapy in England: radical changes in 
the last decade. Ann r Coll Surg Engl 2010; 92: 341–346.
11. rabe E, otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using 
standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc 
Endovasc Surg 2008; 35: 238–245.
12. Yamaki T, Nozaki M, Iwasaka S. Comparative study of duplex-guided foam sclerotherapy and duplex-
guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatol Surg 2004; 
30: 718–722.
13. rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A, Eklof B. randomized clinical trial comparing 
endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great 
saphenous varicose veins. Br J Surg 2011; 98: 1079–1087.
14. Hamel-Desnos C, ouvry P, Benigni JP, Boitelle G, Schadeck M, Desnos P et  al. Comparison of 1% and 
3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, 
double-blind trial with 2 year-follow-up. ‘The 3/1 Study’. Eur J Vasc Endovasc Surg 2007; 34: 723–729.
15. Barrett JM, Allen B, ockelford A, Goldman MP. Microfoam ultrasound-guided sclerotherapy treatment 
for varicose veins in a subgroup with diameters at the junction of 10 mm or greater compared with a 
subgroup of less than 10 mm. Dermatol Surg 2004; 30: 1386–1390.
16. Beale rJ, Gough MJ. Treatment options for primary varicose veins – a review. Eur J Vasc Endovasc Surg 
2005; 30: 83–95.
17. Teruya TH, Ballard JL. New approaches for the treatment of varicose veins. Surg Clin North Am 2004; 84: 
1397–1417, viii–ix.
18. Darvall KA, Bate Gr, Adam DJ, Bradbury AW. recovery after ultrasound-guided foam sclerotherapy 
compared with conventional surgery for varicose veins. Br J Surg 2009; 96: 1262–1267.
19. Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ. The Dutch tariff: results and arguments 
for an effective design for national EQ-5D valuation studies. Health Econ 2006; 15: 1121–1132.
20. Fleiss JL. Statistical Methods for rates and Proportions (2nd edn). John Wiley: New York, 1981.
21. Ten Cate-Hoek AJ, Toll DB, Buller Hr, Hoes AW, Moons KG, oudega r et al. Cost-effectiveness of ruling out 
deep venous thrombosis in primary care versus care as usual. J Thromb Haemost 2009; 7: 2042–2049.
22. Wright D, Gobin J, Bradbury A. Varisolve polidocanol microfoam compared with surgery or sclerotherapy 
in the management of varicose veins in the presence of trunk vein incompetence: European randomized 
controlled trial. Phlebology 2006; 4: 180–190.
23. Ceulen rP, Bullens-Goessens YI, Pi-Van de Venne SJ, Nelemans PJ, Veraart JC, Sommer A. outcomes and 
side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% 
polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatol Surg 2007; 33: 
276–281.
24. Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: report of a 
prospective multicenter registry of 12 173 sclerotherapy sessions. Dermatol Surg 2005; 31: 123–128.
25. Subramonia S, Lees T. radiofrequency ablation vs conventional surgery for varicose veins – a comparison 
of treatment costs in a randomised trial. Eur J Vasc Endovasc Surg 2010; 39: 104–111.
26. Allegra C. Chronic venous insufficiency: the effects of health-care reforms on the cost of treatment and 
hospitalisation – an Italian perspective. Curr Med res opin 2003; 19: 761–769.
27. oostenbrink JB, Koopmanschap MA, rutten FFH. Handleiding voor Kostenonderzoek: Methoden en 
richtlijnprijzen voor Economische Evaluaties in de Gezondheidszorg. College voor Zorgverzekeringen: 
Amstelveen, 2000.

Chapter 4
How specific are venous symptoms for 
diagnosis of CVD?
Van der Velden SK, Shadid NH, Nelemans PJ, Sommer A
Submitted to Phlebology 
 54 Chapter 4
Abstract
Objective: The objective of this study is to evaluate whether and which ‘venous’ symptoms 
are characteristic for patients affected with chronic venous disease (CVD) compared to 
patients with other diseases of the lower limbs (e.g. arthrosis, peripheral arterial disease, 
spinal disc herniation). 
Methods: A cross sectional study was performed to compare the frequency of venous 
symptoms among 76 patients with chronic venous disease (CVD) and reflux and 74 patients 
with other diseases of the legs without reflux.  The VEINES-Sym of the VEINES-QoL/Sym 
questionnaire was used to evaluate the frequency of symptoms. Demographic, clinical 
classification and ultrasound findings were also noted. 
Results: A total of 122 patients were included for analysis (response rate of 87%). Presence 
of venous symptoms was slightly more often reported in the CVD group than in the non-
CVD group, but differences were small and statistically non-significant. Severity of CVD as 
classified by the CEAP classification was not associated with higher proportions of patients 
reporting symptoms than in non-CVD patients, except for swelling (p=.016) and itching 
(p=.007) in C3-C6 patients. The largest difference between the CVD and non-CVD group 
was observed for the time of the day at which symptoms were most intense; patients with 
CVD were more likely to experience symptoms at the end of the day (p<.001).
Conclusions: The small differences in prevalence of reported “venous” symptoms between 
CVD patients and patients with other diseases of the legs suggest that these symptoms may 
be less specific for patients with refluxing veins than is usually assumed.
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Introduction
Chronic venous disease (CVD) is a common health problem in Western countries affecting 
about one quarter of the adult population1. It is commonly assumed that this condition is 
associated with symptoms such as tingling, aching, burning, pain, muscle cramps, swelling, 
sensation of throbbing or heaviness, itching skin, restless legs, leg-tiredness and/or fatigue. 
In daily practice, the presence of one or more venous symptoms, together with clinical and 
duplex ultrasound findings of venous disease is an indication for the treatment of varicose 
veins.
However, equivocal results from previous studies suggest that the association between 
chronic venous disease and venous symptoms may not always be that strong as is assumed 
and that these symptoms may also have a non-venous cause2,3. Furthermore, it has been 
observed that despite successful treatment of the refluxing saphenous trunk, reduction 
of symptoms such as restless legs, oedema, cramps, pain and heavy or tired feeling, was 
reached in only part (40-83%) of the treated patients4-6. Alternatively, local recurrences of 
varicose veins or recanalized refluxing veins on duplex ultrasound are not always correlated 
with the presence of symptoms7,8. These observations raise the question, to what extent 
venous symptoms are specific for patients with CVD and reflux. 
The prevalence of chronic venous disease is increasing with age and in particular the older 
population is affected with CVD1. In this population, the relationship between symptoms 
and presence of reflux may be further obscured by the presence of other diseases of the 
lower limbs, such as hip or knee arthrosis, peripheral arterial disease or spinal disc herniation 
which may cause comparable symptoms in the leg. The present study explores this issue 
by comparing the distribution of symptoms between a patient group with chronic venous 
disease and a patient group with other diseases of the legs. The underlying hypothesis 
was that the so-called venous symptoms (tingling, aching, burning, pain, muscle cramps, 
swelling, sensation of throbbing or heaviness, itching skin, restless legs, leg-tiredness and/or 
fatigue) are non -specific for patients with chronic venous disease. The secondary objective 
was to compare the mean number of symptoms, the mean symptom score and the time of 
the day at which symptoms were experienced as most intense. 
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Methods 
Patients
This study was performed in the outpatient clinics of Dermatology, Neurology, Vascular 
surgery and orthopaedics at the Maastricht University Medical Centre between November 
2010 and June 2011.  Eligible were patients older than 18 years visiting the outpatient 
department of Dermatology with one or more venous symptoms. Patients of the outpatient 
departments of Vascular Surgery, orthopedics or Neurology visiting because of complaints 
of the leg(s) due to peripheral arterial disease (PAD), knee or hip arthrosis (Ar) or spinal disc 
herniation (SDH), respectively, were also eligible. Diagnosis was confirmed by ankle brachial 
index and arterial pulse- wave Doppler recordings, X-ray or Magnetic resonance imaging 
(MrI), respectively.
A trained physician examined patient’s affected legs and classified them according 
to the clinical component (‘C’) of the CEAP classification9. Venous signs, such as 
telangiectasia, reticular veins, varicose veins, edema, skin changes (hyperpigmentation, 
lipodermatosclerosis) or ulceration were recorded. Subsequently, ultrasound examination 
of both superficial and deep venous systems was performed in standing position10. 
All patients in the CVD group had to have symptoms of venous disease and confirmed 
saphenous trunk reflux (>0.5 seconds) on duplex ultrasound. Patients with other diseases 
of the legs (peripheral arterial disease, knee or hip arthrosis or spinal disc herniation) were 
excluded if saphenous trunk reflux of more than 0.5 seconds on duplex ultrasound was 
observed. We hypothesized that patients affected with clinical classes C5 or C6 would 
report more symptoms than patients affected with C1-C4 disease11. However, in clinical 
practice, C5 or C6 disease is relatively rare in patients affected with varicose veins compared 
to the other clinical classes. Therefore, we aimed to include 20 patients with healed or active 
ulceration of the lower leg.  
Patients gave written informed consent to participate in the study.
Questionnaire
Patients were asked to complete the VEINES- Sym of the VEINES-QoL/Sym questionnaire12. 
Patients were requested to complete the questionnaires at home and return it by prepaid 
mail. In case of missing questionnaire items, patients were contacted by phone in order to 
retrieve the missing data. 
The VEINES-Sym is part of the VEINES-QoL/Sym questionnaire and measures symptom 
frequency and severity. The VEINES-Sym consists of ten  items including nine venous 
symptoms (heavy legs, aching legs, swelling, night cramps, heat or burning sensation, 
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restless legs, throbbing, itching, tingling sensation) rated on a five-point scale of frequency 
(1=every day, 2=several times a week, 3=about once a week, 4=less than once a week, 
5=never) and leg pain, rated on a 6-point scale of intensity (1= very severe, 2=severe, 
3=moderate, 4=mild, 5=very mild, 6=none). In this study, we focused on these nine venous 
symptoms  of frequency. In addition, descriptive information concerning the time of the 
day at which the symptoms are experienced most intensely was recorded (e.g. on walking, 
at mid-day, at the end of the day, during the night, at any time of the day, never).  Summary 
symptom scores (VEINES-Sym) were computed from these ten  items. The presence of lower 
VEINES-Sym scores indicates more severe symptoms (range 0-100). 
Statistical analysis 
Patients were categorized into two groups according to the reported frequency of 
symptoms: ‘every day/several times a week/about once a week/less than once a week’ versus 
‘never’. Proportions and absolute numbers of patients who reported presence of a specific 
symptom were compared between patients with and without CVD using the Chi-square 
test. In an additional analysis subgroups of patients reporting a specific symptom ‘every day’ 
was compared to the subgroup of patients who experienced that specific symptom less 
than every day several times a week or less.  
Patients with missing scores on three or more items were excluded from the analysis. For 
patients with missing scores on one or two items, missing values were imputed by median 
values on the completed items reported by an individual. To calculate VEINES-Sym scores, 
raw scores were first transformed to z score equivalents (mean 0; standard deviation 1) 
which then are transformed to T scores (mean 50, standard deviation 10)12. 
All analyses were performed using SPSS (SPSS Inc., Chicago, IL, U.S.A.). Two sided P values of 
0.05 or less were considered to indicate statistical significance. 
Results 
Study population
Eligible were 76 CVD patients with confirmed reflux and 74 patients with Ar, SDH or PAD 
without clinical signs of CVD (25 Ar, 23 SDH, 26 PAD) (Figure 1).
A total of 132 patients completed the questionnaire. The response rate was 88% (69/77) in 
the CVD group and 86% (64/74) in the group with other diseases of the legs. Questionnaires 
were incomplete in 10 patients resulting in a total sample of 122 patients remaining for 
analysis. 
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Eligible PAD
patients (n=26)
Eligible arthrosis
patients (n=25)
Eligible SDH
patients (n=23)
Eligible CVD
patients  with 
reflux(n=76)
3 non 
responders
5 non 
responders
3 non 
responders
8 non 
responders
23 completed
the questionnaire
20 completed
the questionnaire
21 completed
the questionnaire
68 completed
the questionnaire
2 incomplete
questionnaires
3 incomplete
questionnaires
0 incomplete
questionnaires
5 incomplete
questionnaires
59 patients included 63 patients included
Figure 1. Flowchart. Abbreviations: PAD, peripheral arterial disease; SDH,  spinal disc herniation; Ar, arthrosis; CVD, 
chronic venous disease.
Table 1 summarizes the distribution of baseline characteristics in the various subgroups. It 
can be observed that 62% of the patients with CVD were female and the mean age was 61 
years (SD 13, range 30-94; table 1). In the non-venous disease group, half of the patients 
were female and the mean age was 59 years (SD 12, range 32-83). Five patients (8%) of the 
CVD group showed a combination of superficial and deep venous insufficiency. one patient 
only had deep venous insufficiency. C3-C6 venous disease was present in 57% of the CVD 
group and in 7% of the patients in the group with other leg diseases.
Presence of venous symptoms according to diagnosis 
Seven out of nine symptoms (heavy legs, aching legs, swelling, night cramps, restless legs, 
itching and tingling) were reported by more than 50% of the patients in the CVD group. 
This finding is in contrast to the patients in the non-CVD group where only four out of nine 
symptoms (heavy legs, aching legs, night cramps and tingling) were reported by more than 
half of the patients (Figure 2). Higher proportions in the CVD group were observed for six 
symptoms: heavy legs (67% vs 61%), swelling (52% vs 31%,), night cramps (71% vs 53%), 
restless legs (51% vs 47%), throbbing (40% vs 29%) and itching (52% vs 31%); (Table 2.) 
However, no statistical significance was reached. Presence of aching legs, heat or burning 
sensation and tingling was reported by a higher proportion of patients in the non-CVD 
group (Table 2).
When patients were categorized according to frequencies of symptoms every day versus  less 
than every day, the differences in proportions of patients between both groups increased 
only for aching legs (32% vs 49%, p=0.05).
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Table 1. Distribution of patient characteristics.
CVD, n(%) SDH, n(%) PAD, n(%) AR, n(%)
Sex
Male 24 (38%) 13 (62%) 13 (62%)  4  (24%)
Female 39 (62%)  8  (38%)  8  (38%) 13 (76%)
Age
Mean 61 52 64 62
(SD, min-max) (13, 30-94)      (12, 33-83) (9, 45-80) (12, 36-83)
Clinical classes
C0 0 5 (24%) 11 (52%) 3 (18%)
C1 7 (11%) 13 (62%) 5 (24%) 12 (72%)
C2 20 (32%) 2 (10%) 3 (14%) 1 (5%)
C3 16 (25%) 1 (4%) 2 (10%) 1 (5%)
C4 2 (3%) 0 (0%) 0 (0%) 0 (0%) 
C5 1 (2%) 0 (0%) 0 (0%) 0 (0%) 
C6 17 (27%) 0 (0%) 0 (0%) 0 (0%) 
reflux
Superficial system 63 (100%) 0 (0%)  0 (0%)  0 (0%) 
Perforating veins  1 (2%)  0 (0%)  0 (0%)  0 (0%) 
Deep system  6 (10%)  0 (0%)  0 (0%)  0 (0%) 
Abbreviations: CVD, chronic venous disease; PAD, peripheral arterial disease; SDH,  spinal disc herniation; Ar, arthrosis.
Figure 2. Proportions of patients with presence of symptoms among patients with chronic venous disease (CVD) and 
‘other’ non-CVD patients (including; arthrosis, peripheral arterial disease, spinal disc herniation). 
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Clinical severity and presence of symptoms
Patients in the CVD group were categorized according to clinical classes (C1-C2 versus C3-
C6) and these categories were compared with the non-CVD group (Table 2). The difference 
in proportion of patients with presence of symptoms between the CVD and non-CVD group 
increased for the symptoms swelling, night cramps, throbbing and itching if only the CVD 
patients with clinical class C3-C6 were taken into consideration.  In the latter comparison, 
statistically significant difference was reached for the symptoms swelling (p=.016) and 
itching (p=.007)  When we categorized patients according to frequencies of symptoms 
‘every day’  versus ‘less than every day’ the differences between the CVD with clinical class 
C3-C6 and non-CVD group did not increase.  
Number of venous symptoms according to diagnosis 
Patients were allocated according to the number of reported symptoms (out of a total of nine) 
into four groups: 0 symptoms, 1-3 symptoms, 4-6 symptoms and 7-9 symptoms. In both the 
CVD and non-venous group 44% of the patients presented with 4-6 symptoms (Figure 3). 
In addition, the proportion of patients with 7-9 symptoms in the CVD group was not much 
higher than in patients affected by other diseases of the leg (29% versus 14%). 
When we calculated the summary Sym-scores of the non-CVD and CVD group, both groups 
showed similar mean scores (50 versus 51). Mean Sym-scores decreased when we compared 
clinical classes C3-C6 to clinical classes C1-C2 (49 versus 51), indicating a deterioration of 
symptoms.
Table 2. Proportions of patients with presence of symptoms among patients with chronic venous disease (CVD), 
categorized according to clinical class, and ‘other’ non-CVD patients (including: arthrosis, spinal disc herniation and 
peripheral arterial disease). 
Non-CVD 
N=59
CVD 
N=63
CVD (C1-C2)
N=27
CVD (C3-C6)
N=36
Heavy legs 61% 67% 70% 64%
Aching legs 78% 73% 74% 72%
Swelling 31% 52% 48% 56%
Night cramps 53% 71% 70% 72%
Heat/burning 41% 38% 37% 39%
restless legs 47% 51% 59% 44%
Throbbing 29% 40% 30% 47%
Itching 31% 52% 44% 58%
Tingling 63% 54% 63% 47%
 How specific are venous symptoms for diagnosis of CVD?   61
Ch
ap
te
r 4
Time of the day at which symptoms are experienced most intensely
For half of the patients with CVD symptoms were most intense at the end of the day versus 
21% of patients affected by other disease of the legs (p <.001) (Figure 4). The latter group of 
patients was more likely to experience their symptoms at any time of the day (40%). 
Figure 3. Proportions of patients with a total number of 0, 1-3, 4-6 and 7-9 symptoms according to diagnosis.
Abbreviation: CVD, chronic venous disease. other includes: patients affected with arthrosis, spinal disc herniation 
and peripheral arterial disease.
Figure 4. Time of the day that symptoms are experienced most intense. 
Abbreviation: CVD, chronic venous disease. other includes: patients affected with arthrosis, spinal disc herniation 
and peripheral arterial disease.
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Discussion
This study showed that the majority of symptoms that are commonly attributed to chronic 
venous disease (heavy legs, swelling, night cramps, restless legs, throbbing and itching) are 
slightly more often  reported in patients affected by chronic venous disease compared to 
patients affected with other diseases of the lower legs. Furthermore, there was no strong 
correlation between type of symptoms and extent and severity of CVD. When CVD patients 
with clinical class C3-C6 were compared with patients with other leg diseases, differences 
were small and statistical significance was only reached for the symptoms swelling 
and itching. The largest difference between the CVD and non-CVD group was observed 
with respect to the timing of symptoms. Patients with CVD are more likely to experience 
symptoms at the end of the day than patients who have symptoms due to other diseases 
of the legs. 
In the present study the mean VEINES-Sym summary score was comparable to that found in 
other studies 11,13. Kahn et al reported mean Sym scores of 50.5 in males and 49.8 in females. 
As Kurz et al already demonstrated, mean Sym scores decrease with higher clinical classes, 
ranging from 52.3 for clinical class 1 to 43.1 for clinical classes C5-C613. However, although 
mean scores were slightly lower in clinical classes C3-C6 versus clinical classes C1-C2, a 
significant decrease in mean Sym scores with increasing severity could not be confirmed 
in this study.  
The considerable overlap between venous symptoms reported by patients with chronic 
venous disease and by patients with other diseases of the lower leg confirms lack of 
specificity of symptoms. Marston et al14 postulated that none of the venous symptoms are 
specific to venous disease and multiple etiologies may be confused with chronic venous 
disease. The population based Bonn Vein Study revealed that 62.1% of women and 49.1% 
of men reported leg symptoms, but only 27,8% of men and 34,1% of women had CVD 
with clinical class above C2 and only 21.0% had reflux in the superficial venous system15, 16. 
The Edinburgh Vein Study also showed that lower limb symptoms are not only caused by 
venous problems. Venous symptoms such as aching and cramps were reported by 54% 
and 34%, respectively, in the general population3. The San Diego Population study related 
symptoms to venous disease and found that swelling, heaviness and itching were reported 
by participants with visible or functional venous disease about twice as often than by 
participants with normal legs, but for other symptoms the contrasts were less strong2. 
Interestingly, we observed a statistically significant difference between both groups 
in proportion of patients that experienced their symptoms most intensely at the end of 
the day. This finding is in line with another study that showed that circumstances that 
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elicit or exacerbate symptoms were more characteristic for CVD rather than the number 
of symptoms or symptom type17. Several studies already emphasized the importance 
of a thorough medical history to evaluate the circumstances that elicit and exacerbate 
symptoms (the time of the day, relief of symptoms by elevation of the legs) and physical 
examination in combination with venous ultrasound examination14,17,18. However, available 
questionnaires do not incorporate questions, which explicitly address such symptom 
provoking factors.  The reason why we used the VEINES-Sym for this study is that it is 
the most thorough and comprehensive questionnaire on symptom type and symptom 
frequency that is currently available.  other questionnaires such as the Chronic Lower Limb 
Venous Insufficiency (CIVIQ), and Aberdeen Varicose Vein Questionnaire (AVVQ) rather focus 
on impairment of health related quality of life and clinical class related items and to a lesser 
extent on symptoms 19,20.  The VEINES-Sym questionnaire includes one question concerning 
at what time of the day the symptoms are most intense. However, precisely this question is 
not included for calculation of the mean summary Sym-scores and is only used to provide 
descriptive information12. 
The present study has a few limitations. First, the relatively small group of patients could 
be an explanation for the lack of statistically significant differences between both groups. 
The sample size in this study allowed for detection of absolute differences of 25% or more 
in proportions of reported symptoms with a power of 90% and two-sided alpha of 5%. It 
was assumed that for discriminative purposes substantial differences in proportions are 
required and that in this respect detection of smaller differences may not be very relevant. 
Second, we did not include a control group of healthy subjects and therefore we were not 
able to compare the results of the patients with CVD to the proportion of healthy patients 
reporting symptoms.
In conclusion, the lack of difference in prevalence of reported “venous” symptoms between 
CVD patients with confirmed reflux and patients with other diseases of the legs suggest 
that these symptoms may be less specific for patients with refluxing veins than is usually 
assumed. This finding implies that venous symptom questionnaires that only address type 
and frequency of these symptoms may have limited ability to identify patients with CVD 
and reflux. There seems to be room for improvement of questionnaires for CVD, including 
specific questions about circumstances that elicit and exacerbate or alleviate symptoms. 
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Abstract
Four days after foamsclerotherapy of an incompetent great saphenous vein of the left 
lower leg a 49-year-old woman developed a superficial thrombophlebitis of the venous 
dorsal arch. In the course of follow-up repeated color duplex sonography initially did 
not show involvement of the deep venous system and, hence, she was treated with non-
steroidal anti-inflammatory drugs and compression hosiery. However, six weeks after 
foam treatment we diagnosed a deep venous thrombosis (DVT) of the popliteal vein and 
started an oral anticoagulant therapy. Although rarely observed, DVT is among the most 
serious complications of foamsclerotherapy Therefore, we suggest that the occurrence of a 
superficial thrombophlebitis that is not located in close vicinity of the vein treated should 
be an indication for regular follow-up examinations to prevent missing the occurrence of 
disease progression and a possible involvement of the deep venous system.
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Introduction
Varicose veins are one of the most common blood vessel problems in the general population. 
With a female preponderance, the prevalence of varicoses increases with age.1
For decades, surgery has been the therapy of first choice for the treatment of patients with 
venous diseases of the lower limb attributable to truncal saphenous incompetence.2 The 
introduction of vascular ultrasound, however, has led to an interest in distinct therapeutic 
endovenous obliteration techniques, including radiofrequency methods, endovascular laser 
treatment, and foam sclerotherapy. Ultrasound-guided sclerotherapy with foam is a novel 
further development of traditional sclerotherapy, and several studies have demonstrated 
great effectiveness of 70-93% in the closure of saphenous trunks by this technique.2,3
Foam sclerotherapy constitutes a minimally invasive treatment modality for varicose 
veins that is patient friendly, safe, inexpensive, easy to use in experienced hands, requires 
only a minimum of equipment, and has a low complication rate. It is a chemical ablation 
technique that induces endothelial cell destruction, leading to the formation of a clot. A 
fully organized thrombus is usually formed after 4 weeks and, eventually, intimal fibroplasia 
results in endofibrosis.3
Case Report
A 49-year-old woman was referred to our phlebology outpatient unit with complaints of 
heaviness, tiredness, and cramps in both legs. Her medical history revealed a saphenofemoral 
ligation and a short stripping of the great saphenous veins (GSVs) in both legs. Her general 
health status was good and her further medical history was unremarkable apart from 
menopausal transition problems that were being treated with ethinylestradiol/gestodene 
(Femodene®).
on physical examination, there were some telangiectatic and reticular veins on both legs, 
but no other signs indicative of chronic venous insufficiency. Color duplex sonographic 
examination revealed an insufficiency of the right small saphenous vein (SSV), but the 
remaining superficial and deep venous system was sufficient. Her left leg showed a recurrent 
GSV with an insufficiency extending from the Hunter perforans (mid-thigh perforans) to 
the ankle. No incompetent perforating veins were observed and the further superficial and 
deep systems were sufficient.
The insufficient right SSV was treated with endovascular laser therapy. For the recurrent left 
GSV, foam sclerotherapy was applied using a single 4 ml injection of 3% polidocanol foam 
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administered 15 cm below the knee upwards to the point of strongest reflux. Subsequently, 
a pelotte and elastic stockings were applied. Four days after treatment, however, the patient 
returned to the department with a very painful and swollen left foot (Figure 1).
on clinical examination, a pitting edema was noted on the medial aspect of the foot, 
malleolus, and distal part of the lower leg. Duplex sonography showed a non-compressible 
venous dorsal arch and an open and sufficient deep venous system (Figure 2). A diagnosis of 
superficial thrombophlebitis was made and the patient was started on combination therapy 
with diclofenac 3 × 50 mg/day, pantoprazole 20 mg/day, and compressive bandaging. 
To detect possible progression into the deep venous system, duplex sonography was 
performed twice weekly. After 6 weeks, the edema and pain had almost completely resolved.
Figure 1. Pitting edema in the left foot                                                           Figure 2. Anatomy of the dorsal arch vein
Dorsal 
venous 
arch and 
network
Greater
saphenous
vein
Figure 3: Deep venous thrombosis in the left popliteal vein
 Superficial thrombophlebitis and DVT after foam sclerotherapy 71
Ch
ap
te
r 5
Nevertheless, an ultrasound examination after week six of follow-up showed a clot in the 
center of the left popliteal vein with some surrounding rest-flow, diagnosed as deep venous 
thrombosis (DVT) (Figure 3). The femoral vein and calf veins were not affected.
Discussion
Thrombus formation in a superficial vein can lead to superficial thrombophlebitis. This 
complication of foam sclerotherapy has an incidence in the range 4.4–32%.4,5 Superficial 
thrombophlebitis commonly resolves without specific therapy. If, however, treatment of 
superficial thrombophlebitis is administered, it mostly consists of anti-inflammatory drugs, 
such as aspirin or ibuprofen, which also help to relieve the pain. In addition, supportive 
compression hosiery can be applied. It can take from several days to weeks for the clot to 
resolve and for the symptoms to disappear completely.
only seldom does superficial thrombophlebitis after foam sclerotherapy progress to a severe 
medical complication, as observed in our patient. recently, Jia et al.6 reviewed 29 studies 
and showed that the median rate of serious adverse events, such as pulmonary embolism 
and deep venous thrombosis (DVT), was less than 1%.5 This percentage is comparable with 
the incidences of DVT after surgical procedures and after different endovenous treatment 
regimens for varicose veins. Nevertheless, it is important to emphasize that, in patients 
with varicoses, the incidence of DVT is higher than that in the general population, and 
therefore a causal correlation with foam sclerotherapy may not even exist.7 Without doubt, 
however, there is a strong association of superficial thrombophlebitis with DVT, as the latter 
complication is significantly more frequently (6–44%) observed in patients with a preceding 
diagnosis of superficial thrombophlebitis.8
our patient initially developed a superficial thrombophlebitis in the arcus venosus 
superficialis dorsalis after foam sclerotherapy (Figs 1 and 2). Possibly, a part of the foam 
injected into the great saphenous vein (GSV) below the left knee ran in a retrograde 
direction towards the venous dorsal arch of the left foot and, eventually, progressed to DVT 
of the popliteal vein (Fig. 3). Another possibility is that a portion of the foam directly spread 
into a perforator vein and DVT commenced from there. 
If serious complications occur after foam sclerotherapy, additional risk factors are likely to 
play a role. These include the use of high doses of foam, as well as the treatment of truncal 
saphenous or incompetent perforating veins.9 The individual presented here had been 
on postmenopausal hormone therapy for 6 months, and it is well known that treatment 
with ethinylestradiol/gestodene (Femodene®) is associated with an increased risk of DVT, 
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in particular within the first year. Thus, the combination of superficial thrombophlebitis 
and hormone therapy, as observed in our patient, constitutes an even higher risk for the 
development of DVT.
Although a rare complication of foam sclerotherapy, DVT is one of the most serious. 
Therefore, we strongly believe that the occurrence of a superficial thrombophlebitis that 
is not located in the immediate vicinity of the treated vein constitutes an indication for 
repeat follow-up examinations by duplex sonography until phlebitis has resolved, in order 
to recognize disease progression and possible involvement of the deep venous system.
Conflicts of interest
The authors have declared no conflicts of interest.
References
1. Abbade L, Lastória S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J 
Dermatol 2005;44:449 –456.
2. rabe E, otto J, Schliephake D, et al. Efficacy and safety of great saphenous vein sclerotherapy using 
standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc 
Endovasc Surg 2008;35:238–245.
3. Hamel-Desnos C, Desnos P, Wollmann JC, et al. Evaluation of the efficacy of polidocanol in the form 
of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. 
Dermatol Surg 2003;29:1170 –1175
4. Ceulen rP, Bullens-Goessens YI, Pi Vandevsj Nelemans PJ, et al. outcomes and side effects of duplex-
guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol 
foam: results of a randomized controlled trial with 1-year follow-up. Dermatol Surg 2007;33:276 – 281.
5. Jia X, Mowatt G, Burr JM, et al. Systematic review of foam sclerotherapy for varicose veins. Br J Surg 
2007;94:925 –936.
6. Bohler K, Baldt M, Schuller-Petrovic S, et al. Varicose vein stripping – a prospective study of the 
thrombotic risk and the diagnostic significance of preoperative color coded duplex sonography. 
Thromb Haemost 1995;73: 597– 600.
7. Guex JJ, Allaert FA, Gillet JL, et al. Immediate and midterm complications of sclerotherapy: report of a 
prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005;31:123 –128.
8. Wichers IM, Di Nisio M, Buller Hr, et al. Treatment of superficial vein thrombosis to prevent deep vein 
thrombosis and pulmonary embolism: a systematic review. Haematologica 2005; 90: 672 – 677.
9. Alos J, Carreno P, Lopez JA, et al. Efficacy and safety of sclerotherapy using polidocanol foam: a 
controlled clinical trial. Eur J Vasc Endovasc Surg 2006;31:101–107.


Chapter 6
In vivo effects of foam sclerotherapy 
on coagulation
N H Shadid, S K van der Velden, r van oerle, H ten Cate, A Sommer 
and P Nelemans
Phlebology. 2013 Mar 27. [Epub ahead of print]
 76 Chapter 6
Abstract
Objective: The aim of this study was to evaluate whether foam sclerotherapy (FS) induces 
changes in CAT (calibrated automated thrombinography) and other coagulation parameters 
which could indicate an increased risk of thrombotic events.
Methods: Blood samples from eight patients treated with FS were taken before treatment 
and 30 minutes, one and four hours and one week after treatment. CAT parameters (ETP1n, 
Peak1n, Lag time 1), thrombin antithrombin complexes (TAT), d-dimers, fibrinogen, Von 
Willebrand (vWf Ag) factor and platelet-derived microparticles (MIPAs) were measured. 
Results: Significant changes over time for Peak1n, fibrinogen, d-dimers, vWfAg and TAT 
complexes were observed. CAT parameters decreased over time, except for Lag time 1. 
D-dimers and TAT complexes increased and fibrinogen, vWf Ag, MIPA’s decreased during 
the first hours.
Conclusion: The findings in this study support the hypothesis that FS initiate coagulation 
pathways, but there is no evidence that this activation results in an increased thrombosis 
risk.
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Introduction
Foam sclerotherapy (FS) is a minimally invasive technique for the treatment of varicose 
veins. Next to other endovenous ablation techniques it is becoming more popular due to 
the demand for minimally invasive and less expensive procedures.1–3 FS seems to be an 
effective and safe therapy in treating venous insufficiency.4,5 The aim of FS is to obliterate 
the lumen of the incompetent varicose vein. Successfully treated veins are transformed into 
fibrous cords and the functional result corresponds to surgical removal of a varicose vein.6
By inducing vessel wall injury, detergent sclerosants might be expected to initiate the same 
coagulation pathways that ultimately lead to the generation of thrombin and formation of 
a fibrin clot.7 The risk of postsclerotherapy deep venous thrombosis (DVT) is approximately 
1%. The fact that FS can induce a hypercoagulable state and that some patients may be at 
an increased risk of thrombotic events remains a concern for each specialist.5
recently, Parsi et al. studied the in vitro effects of polidocanol on the coagulation 
system. They showed that whereas high concentrations of polidocanol achieve some 
anticoagulant activity, low concentrations induce the release of procoagulant platelet-
derived microparticles.8 Furthermore they demonstrated the clot kinetics of sclerosants by 
thromboelastography: strong clots were initiated at low concentrations and clot formation 
was prevented at higher concentrations.9 Hamel-Desnos et al.10 assessed the consequences 
of FS in vivo, showing that FS made from polidocanol had only a minimal effect on peripheral 
blood. Fabi et al.11 reported that foam made from sodium tetradecyl sulphate (STS) does not 
affect coagulation parameters.
Thrombin is central to the coagulation process, but classical clotting tests, such as the 
activated partial thromboplastin time and prothrombin time assess only time to initiation 
of clot formation and do not reflect thrombin generation. In vitro, more than 95% of 
thrombin generation occurs after the initial formation of fibrin, which means that traditional 
coagulation tests account for less than 5% of the overall thrombin potential. Calibrated 
Automated Thrombography (CAT) measures the activity of free thrombin and enables a 
continuous measurement of thrombin generation in plasma.12,13
It has been hypothesized that major parameters of the resulting thrombogram, such as 
endogenous thrombin potential (ETP) and peak height (Peak) correlate with hypercoagulable 
states and increased risk of thrombotic events.12 The objective in this pilot study is to evaluate 
whether FS induces changes in coagulation parameters compared with baseline that could 
indicate an increased risk of thrombotic events as measured by CAT. To the best of our 
knowledge this test has never been used in the setting of sclerosants. The effects observed 
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in this global assay were further analysed using selected determinants of hemostasis and 
activated clotting, including thrombin antithrombin complexes (TAT), d-dimers, fibrinogen, 
Von Willebrand (vWf Ag) factor and platelet-derived microparticles (MIPAs).
Methods
Study subjects
Patients with varicose veins were recruited at the outpatient clinic of Dermatology. Patients 
were eligible if they were scheduled for foamsclerotherapy of the great saphenous vein, 
small saphenous vein or anterior accessory saphenous veins. Subjects were excluded if they 
had a history of coagulation disorders or thromboembolic processes, used anticoagulation 
or antiplatelet medication, were pregnant at the time of the treatment, had signs of DVT on 
venous ultrasound, suffered from immobility or had a short life-expectancy.
After informed consent was obtained, eight patients were included and were all treated with 
foamsclerotherapy. The polidocanol (3% Aethoxysklerol®, Kreussler Pharma, Wiesbaden, 
Germany) was prepared using the Tessari’s method in a standard ratio of 1 mL of liquid and 
4 mL of room air.14
 
Subsequently, the foam was directly injected in the affected vein using an 18 gauge venflon 
(B Braun Melsungen, Germany). The treatment was performed by an experienced physician. 
All patients received elastic compression during a period of four weeks, exerting at least a 
23 mmHg ankle pressure (23 mmHg Mediven Plus).
The study was approved by the medical ethics committee of Maastricht University Medical 
Centre. Informed consent was provided from all patients before participating in the study, 
according to the principles of the Declaration of Helsinki.
Blood and plasma collection
Blood samples were taken from each subject at baseline, 30 minutes, one hour, four hours 
and one week after treatment with foam sclerotherapy. This time points were chosen 
based with the hypothesis that because of short half times the most substantial changes 
in coagulation parameters can be expected within the first hours after foam sclerotherapy. 
Parameters were also measured at one week after treatment to observe whether at that time 
point parameters have returned back to baseline levels. Citrated samples were obtained 
through antecubital venipuncture for five times, at the same site. (1 volume trisodium citrate 
0.105 mol/L to 9 volumes blood). A tourniquet was used to better visualize the vein, after 
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puncture the tourniquet was removed and 4 mL of blood was flushed before the citrated 
plasma was collected. Plasma was separated from the cells through centrifugation at 1750 
g for 15 minutes at room temperature. Platelet poor plasma (PPP) was prepared by a second 
plasma centrifugation step at 10,000 g for 10 minutes at room temperature. Samples were 
frozen at -80C.
We measured CAT parameters (ETP, Peak and Lag time) and the following coagulation 
parameters; thrombin antithrombin complexes (TAT), d-dimers, fibrinogen, Von Willebrand 
(vWf Ag) factor and platelet-derived microparticles (MIPAs).
Calibrated Automated Thrombogram (CAT)
CAT was performed by using a 96-well plate fluorescent reader and standard CAT reagents 
supplied by Thrombinoscope (Synapse BV, Maastricht, The Netherlands). Parameters 
of interest were lag time, which was defined as the time to initial thrombin formation in 
minutes, the ETP, which is the area-under-the-curve representing the presence of thrombin 
in time and peak height (Peak), representing the maximal concentration of thrombin 
formed in plasma in (nmol/L).15 Peak height values were calculated as a percentage of 
normal (Peak1n%). Normal Peak1n% values have a range between 60 – 170%.
ETP was triggered by the addition of 20 µL tissue factor, final concentration 1 pmol/L, 
phospholipids (4 µmol/L) and calcium ions to 80 µL of PPP.
Thrombin generation parameters were calculated with standard throm binoscope® 
software program (version 2.2). ETP values are given as thrombin activity throughout the 
time (nmol/L min). Subsequently ETP values were calculated as a percentage of normal 
(ETP1n%). Normalized values were calculated as patients values divided by mean values 
from normal pool plasma multiplied by 100%. Normal ETP1n% values have a range between 
60 and 170%.16
Other coagulation parameters
TAT complexes and d-dimers provide information about the acute phase of coagulation. 
TAT and d-dimers are both measured using enzygnost® (Siemens) and innovance-d-dimer 
(CA7000, Siemens) respectively. The normal values for TAT are below 4.0 mg/mL and <500 ng/
mL for d-dimers. Fibrinogen was measured according to the Clauss method (Siemens) with 
normal values between 1.7 and 3.5 g/L.17 vWf Ag is a marker for endothelial damage and was 
measured using standard reagent (Siemens).18 Normal values have a range between 60% 
and 160% (internal assay validation calibrated against World Health organization standard 
plasma). The MIPAs were measured using the ZYMUPHEN MP-activity kit (Hyphen Biomed). 
Values below 10 nmol/L equivalent phosphatidylserine were considered as normal.
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Study endpoints
The primary endpoint is the change of the ETP over time based on the assumption that this 
test best reflects overall coagulation activation status.
Secondary outcomes are changes over time of other coagulation markers and factors, such 
TAT complexes, d-dimers, fibrinogen, vWf Ag and the activity of MIPAs.
Statistical analysis
Median values for parameters over time were plotted in a graph. Median values were used 
because of the small sample size values which are not normally distributed. Differences 
between median values at different time points were tested using a non-parametic test 
for paired samples (Friedman test). The difference of each value compared with baseline 
was tested using the Wilcoxon test. P values ≤0.05 were considered to indicate statistical 
significance. Analyses were performed using SPSS 15.0 for Windows.
Results
Eight patients were included. The average age was 51.1±9.4 years (range 38 – 69 years). 
Seven patients were primarily affected, including three great saphenous veins (38%), four 
accessorial lateral saphenous veins (50%) and one recurrent great saphenous vein (13%). 
The amount of foam injected ranged from 4 to 9 mL. Baseline characteristics are presented 
in Table 1.
Table 1. Baseline characteristics of eight patients treated with foam sclerotherapy
Baseline characteristics
Age (years) 
Female 
Clinical presentation
   C2 
   C3 
Type of vein
   GSV
   Tributary
   recurrent GSV
   Volume of foam (cc)
52.8 (SD 9.8) (range 50 – 69) 
6 (75%)
5 (62.5%) 
3 (37.5%)
3 (37.5%) 
4 (50%) 
1 (12.5%)
5 (SD 1.8) (range 4 – 9) 
GSV, great saphenous vein; SD, standard deviation
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Table 2. Median values of CAT and other coagulation parameters. Differences between median values at different 
time points were tested using a non-parametric test for paired samples (Friedman test).Difference of each value 
compared to baseline was tested using the Wilcoxontest. P-values ≤0.05 are indicated with *
At baseline At 30 min At 1 hour At 4 hours At 1 week p-value
ETP 
(nM.min)
158 
(123.3-190.2)
146 
(113.9-173.5)
138 
(122.5-191.5)
135 
(106.8-191.6)
138* 
(119.3-199.8) 0.126
Peak  
(nM)
243
(169.1-325.3)
203*
(110.4-260.0)
200
(134.3-256.3)
169*
(123.3-275.7)
186*
(157.6-294.7) 0.014
Lag time  
(Min)
5.46
(4.30-7.33)
5.99*
(4.50-8.00)
5.90
(4.33-7.67)
6.00*
(4.60-7.64)
6.06
(4.94-9.31) 0.10
Fibrinogen  
(1.7-3.5g/l)
3.6
(2.4-4.0)
3.30
(2.4-4.1)
3.30*
(2.4-4.0)
3.25*
(2.3-3.9)
3.7
(2.4-4.1) 0.011
D-dimers  
(<500ng/ml)
525*
(189-1187)
719*
(371-3200)
800*
(352-3773)
1021*
(491-4046)
691*
(323-9222) 0.001
vWf Ag  
(60-160%)
111
(79.2-158.8)
106
(78.7-154.7)
107
(79.3-147.9)
104*
(74.4-143.6)
112
(74.8-159.3) 0.005
TAT complexes 
(<4.0 g/ml)
1.83
(1.3-7.1)
2.47
(1.9-16.9)
4.38*
(2.3-11.2)
2.41
(1.9-7.7)
2.14
(0.9-14.0) 0.009
MIPA’s  
(<10nM)
5.33
(4.5-8.8)
6.66
(3.0-10.5)
6.67
(4.4-9.5)
6.46
(4.0-32.9)
7.18*
(4.9-20.9) 0.165
 
Effect on CAT parameters and other coagulation parameters
Median values were calculated at different time points for each individual coagulation 
parameter (see Table 2). With respect to the CAT parameters median values decreased 
over time except for Lag time 1. ETP reached the lowest value at four hours (135%). Peak 
significantly changed over time (P = 0.014) and reached a nadir at four hours (169%) (Table 2, 
Figure 1). Furthermore we detected significant changes for the following coagulation 
parameters; fibrinogen, d-dimers, vWf Ag and TAT complexes. Median value for fibrinogen 
at baseline was 3.6 g/L and decreased to 3.25 g/L at four hours and thereafter it increased 
to 3.7 g/L at one week (P = 0.011). For the d-dimers an increase was observed from 525 ng/
mL at baseline to 1021 ng/mL at four hours and then concentrations decreased to 691 ng/
mL (P =0.001). For vWf Ag the following values were observed: 111%,106%, 107%, 104% 
and 112% (P = 0.005) and for TAT complexes values of 1.83 µg/L, 2.47 µg/L,4.38 µg/L, 2.41 
µg/L, 2.14 mg/L (P = 0.009) were seen. Fibrinogen was decreasing over time and the nadir 
was reached at four hours. The concentration of MIPA’s showed a slightly increase over time 
and reached a peak at one week (7.18 nmol/L) (Table 2, Figure 2).
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Figure 2. Median changes in coagulation parameters over time
Figure 1. Median changes in CAT parameters over time
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Discussion
The main finding in this pilot study is that FS causes a marked and acute activation of 
the coagulation system, illustrated by time-dependent rises in d-dimer and TAT levels, 
indicative of acute thrombin and fibrin formation and digestion, respectively. At the same 
time, the ETP1n and Peak1n decreased slightly over time. These changes in CAT parameters 
are suggestive of a compensatory mechanism that may have an inhibitory effect on the 
potential to generate thrombin. This divergent reaction may imply that in spite of an acute 
procoagulant effect of the sclerosing agent, the tendency to thrombosis (hypercoagulability) 
may be dampened by this, unknown, compensatory mechanism.
Usually high ETP1n values (reflecting the thrombin generation) are predictive for an increased 
risk of venous thrombosis.12,19 Thus, the absence of such rises upon sclerotherapy also 
argues against a major thrombosis risk. The lack of major changes in vWf Ag and fibrinogen 
reflect a lack of activation of vascular endothelium and inflammation, respectively, during 
the course of this local treatment. obviously, any local effects on the vascular endothelium 
are diluted in the systemic circulation and will escape measurement in the venous sample 
collected. The MIPAs show an interesting pattern with a late rise, which in the absence of 
concurrent procoagulant effects may reflect cell death secondary to sclerosis treatment.
Two other studies has reported on the in vivo biological effects of the treatment of FS. 
Hamel-Desnos et al.10 concluded that FS has a minimal effect on coagulation measured in 
peripheral blood. Fabi et al.11 showed that foam made from STS does not affect coagulation 
parameters as measured according to platelet count and concentrations of clotting factors 
and fibrinogen. These studies lead to similar conclusions, despite some differences in 
design. Like Hamel-Desnos we measured fibrinogen, vWf Ag, TAT-complexes and d-dimers. 
In addition we measured MIPA’s which are markers for the activation of thrombocytes, 
endothelial cells and leukocytes. We also added CAT parameters which were used as a 
quantitative measure of the thrombin-forming capacity in plasma samples. In this way, 
we were able to assess the overall hypercoaguability potential. Furthermore, the sampling 
schedule was different. In the study by Hamel-Desnos, laboratory work-up was done on 
days 1, 7, 14 and 28 after FS. In the study of Fabi et al. venous blood was drawn before 
treatment and 15 minutes after treatment. We measured parameters within a couple of 
hours after treatment with foam, as we hypothesized that because of short half times the 
most substantial changes in coagulation parameters would be expected within the first 
hours after FS. Parameters were also measured at one week after treatment to observe 
whether at that time point parameters have returned back to baseline levels.
Except for the studies of Hamel-Desnos and Fabi, we did not find any other studies reporting 
on the effect of FS on coagulation parameters. However, some publications have reported 
on the effect of liquid sclerosants on coagulation.20 – 22
Mason et al. revealed a significant conversion from negative to positive d-dimers levels in 
patients after sclerotherapy of vascular anomalies. However, the sclerosant that was used 
was not polidocanol but sodium tetradecyl sulphate or dehydrated alcohol.21 Bernardi et 
al.22 reported a small reduction of prothrombin and antithrombin activity in patients with 
abnormal coagulation function due to liver cirrhosis who were treated for oesophageal 
varices with slcerotherapy, but these changes did not lead to clinically significant 
deterioration of coagulation. In addition, Suzuki et al.20 reported a small decrease of platelet 
levels after 15 minutes of polidocanol injection in mongrel dogs. Parsi et al. showed that 
polidocanol in vitro caused a mild reduction in Protein C and antithrombin and a moderate 
reduction in Protein S levels.
The results of the above mentioned studies as well as our study suggest that neither liquid 
sclerotherapy nor FS strongly affect the haemostatic system. The observed minimal changes 
in coagulation parameters correspond with the clinical observation that venous thrombolic 
events (VTE) after FS occur in only a small number of cases. The estimated rate of pulmonary 
embolism and DVT was less than 1% after FS in a metaanalysis.23,24 The decrease of ETP1n 
possibly indicates a compensatory mechanism and may explain the finding that venous 
thrombolic events are observed in only a low percentage of patients.
Limitations of this study are the small sample size, the lack of a control group and lack of 
standardization of foam treatment regarding volume.
In conclusion, the findings in this study support the hypothesis that FS initiate coagulation 
pathways, but provide no evidence that this activation results in a hypercoagulable state 
in peripheral blood after treatment, at least in patients without apparent thrombophilic 
defects.
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Abstract
Objective: To investigate which clinical characteristics at baseline are predictive for great 
saphenous vein recurrence following ultrasound-guided foamsclerotherapy (UGFS).
Material and Methods: Data of patients treated for GSV incompetence with UGFS were 
derived from a multicentre prospective randomised controlled trial comparing surgery 
versus UGFS with a follow-up of 2-years. recurrence of reflux was determined on colour 
duplex scans at 3, months, 1 year and 2 years. Univariate and multivariate Cox regression 
analysis was used to evaluate the effect of  gender, age, C of CEAP classification, diameter of 
GSV, injected foam volume, presence of distal GSV reflux, presence of reflux in the anterior 
accessory saphenous vein (AASV) and Venous Clinical Severity Score (VCSS) on risk of 
recurrent reflux.
Results: 225 patients were available for analysis. Treatment after one single session 
was successful in 120 patients and recurrence of saphenous reflux was observed in 105 
patients within 2 years during follow-up. Significant associations with risk of recurrence 
were observed for mid thigh GSV diameter (Hr= 1.012 with 95% CI: 1.002-1.022, p=0.022), 
presence of distal GSV reflux (Hr=1.882 with 95% CI: 1.029-3.443, p=0.040) and presence of 
C4-C5 (Hr=1.509 with 95% CI: 0.882-2.583, p=0.134).
Conclusion: In conclusion, this prospective study suggests  that UGFS treatment for the 
proximal GSV is less effective for patients with a large vein, a refluxing distal GSV and C4-C5 
at baseline.
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Introduction
Lower extremity venous insufficiency is a common health problem in Western countries, 
and its prevalence increases with age. The disease has a substantial impact on patients’ 
quality of life, as well as on the resources and budgets of health care systems1. Insufficiency 
of the great saphenous vein (GSV) is the most common cause of varicose veins of the 
lower extremity and of leg ulcer development2. For many years the standard treatment 
was surgical stripping of the GSV. However, in recent years a variety of minimally invasive 
and less expensive procedures have been used with increasing frequency3. one of these 
techniques is ultrasound-guided foamsclerotherapy (UGFS), which is effective, low in costs, 
easy to perform and can be used for different varicose veins, such as primary varicose veins, 
tortuous veins, tributaries and recurrences4-6.
A recently published randomized controlled trial has shown that UGFS is a cost-effective 
alternative to surgical stripping5. The protocol in the published  trial allowed extra UGFS 
sessions if a recurrent reflux in combination with persistent venous symptoms occurred 
during follow-up. Two years after treatment, the probability of clinically relevant recurrence 
(with presence of symptoms) was similar in the UGFS and surgery groups, but failure to 
eliminate GSV failure was observed in 35% of patients treated by UGFS compared to 21% in 
the surgery group. It can be argued that recurrent reflux alone without symptoms has minor 
clinical relevance, but there is also concern that anatomic recurrence may predispose to 
recurrent veins developing in the future7. For this reason, the aim of the present study was 
to identify patient and treatment characteristics that influence the probability of anatomic 
recurrence of reflux of the GSV after treatment by UGFS. Effectiveness might be improved 
by better patient selection and more tailored treatment.
Methods
Patients
Data were derived from a multicentre randomized controlled trial comparing surgery 
to UGFS in treating primary GSV incompetence with a follow-up of two years. The study 
design and procedures have been described before8. Consecutive patients referred for 
treatment of symptomatic varicose veins by general practitioners were recruited at the 
outpatient dermatology and surgery departments of three hospitals in the southern part of 
the Netherlands. Eligible were patients with a primary GSV incompetence and one or more 
venous symptoms. An incompetent GSV was defined as reflux >0.5s in the saphenofemoral 
junction and GSV (measured over a distance of at least 20 cm in the upper leg).
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Patients with an incompetent deep venous system, signs of a previous deep venous 
thrombosis on duplex imaging, an active ulcer or a contraindication to the use of 
polidocanol were excluded. The trial was approved by the medical ethics committee of 
Maastricht University Medical Centre. All patients provided written informed consent 
before participating in the study, according to the principles of the “Declaration of Helsinki”.
UGFS treatment
The GSV was identified by duplex imaging in the standing position and marked from 
the groin following the path of reflux in the GSV. Sclerosing foam was prepared with the 
double-syringe technique, applying a 1 : 4 ratio of sclerosant : air. one syringe was filled with 
1 ml of 3 per cent polidocanol (Aethoxysklerol®; Kreussler Pharma, Wiesbaden, Germany) 
and the other syringe with 4 ml air. Patients were treated in supine position with an 18-
Fr intravenous cannula (B. Braun, Melsungen, Germany), under direct duplex imaging. The 
cannula was inserted just above the knee. The treatment was considered successful when 
the proximal GSV was completely filled with foam and maximal venospasm was achieved. 
Initially, only the GSV trunk was treated with the hypothesis that refluxing tributaries may 
go into regression. If reflux in large superficial tributaries was present, shortly after the first 
visit, these tributaries were treated by phlebectomies. Treatment with UGFS or phlebectomy 
of refluxing smaller tributaries or small saphenous veins was performed at the planned 
follow-up visits. Compression was applied with a foampad over the treated area and an anti-
embolism (Brevet TX 10 mmHg) stocking for one week, day and night. Elevation of the leg 
or compression of the saphenofemoral junction was not applied.  A Class II elastic stocking 
(23 mmHg Mediven Plus) was prescribed during daytime for six weeks. After treatment, 
patients were instructed to walk for at least 30 minutes, after which they could resume their 
daily activities, including professional activities.
Data collection
Information was available on patient characteristics such as gender and age, clinical 
presentation (C of CEAP classification) and disease extent and severity at baseline. A Venous 
Clinical Severity Score (VCSS) was assigned by the research physician. Presence or absence 
of reflux in both the anterior accessory saphenous vein (AASV) and the distal GSV were 
registered. The diameter of the GSV at baseline was recorded at different levels: upper thigh, 
mid thigh and lower thigh. The diameter was measured in upright position with transversal 
view and the maximum diameter was taken in consideration. After treatment the volume 
of injected foam was noted and duplex examination of the GSV was performed at 3, 12 and 
24 months. recurrent reflux>0.5s was defined as reflux of more than 2 cm in length in the 
treated vein segment (proximal GSV) as measured by colour flow Doppler ultrasonography. 
recurrence of reflux was defined in this study as anatomic recurrence of reflux  irrespective 
of whether the patient reported recurrence of venous symptoms or not. 
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Statistical analysis
Patients with and without anatomic recurrence of reflux were compared with respect to 
patient and treatment characteristics. Categorical variables were expressed as percentages 
and absolute numbers. Continuous variables were expressed as mean values with standard 
deviation (sd)  for variables with a normal distribution or  median values with range for 
variables without a normal distribution.  Between- group comparisons were performed 
using the t-test for independent samples if variables were normally distributed or the 
nonparametric Wilcoxon test for not normally distributed data and the Chi-square test for 
categorical data.
To evaluate the association of clinical characteristics with the risk of recurrence of saphenous 
reflux, univariate and multivariate Cox regression analyses were performed with presence 
or absence of reflux as the dependent variable. Patients were censored at the time of a first 
recurrence. 
Variables associated with p-values <0.15 from univariate  analysis were considered as 
potentially relevant predictors for treatment failure and were simultaneously entered in 
a multivariate Cox regression model  to evaluate the independent effects on treatment 
failure. The magnitude of effect was expressed by hazard ratios (Hr) with 95% confidence 
intervals (CI). For initial selection of potential predictors, p-values <0.15 were considered 
to indicate statistical significance, because p-values ≤ 0.05 may be too strict and result in 
missing identification of relevant variables9. Based on the identified predictors of recurrent 
saphenous  reflux patients were categorized into subgroups. Kaplan-Meier survival analysis 
was used to calculate the observed cumulative probabilities of recurrence free survival with 
95% confidence intervals within subgroups of patients.
All data were analysed using SPSS version 18.0 (SPSS, Chicago, IL, USA and STATA, version 
11.2).
Results
Data of 225 patients treated by UGFS were available for investigation. Treatment after one 
single session was successful in 120 patients and treatment failure was observed in 105 
patients within 2 years during follow-up. Table 1 shows the distribution of baseline clinical 
characteristics for patients with and without recurrence of saphenous reflux.
Hazard ratios (Hr) with 95% CI from univariate analysis for gender, age, clinical presentation 
(C of CEAP classification), diameter of GSV, volume of injected foam, presence of distal 
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Table 1. Baseline characteristics (absolute numbers and proportions or median values with ranges).
  Treatment failure n=105 Treatment success n=120 p-value 
Age(years) 53.0   (SD 13.4) 50.7   (SD 12.9) 0.2
Female gender 78      (74.3%) 90     (75.0%) 0.9
Clinical presentation
C2 84      (80.0%) 100  (83.3%) 0.16
C3 5       (4.8%) 12     (10%)
C4 13     (12.4%) 6       (5.0%)
C5 3         (2.9%) 2        (1.7%)
VCSS 3.0    (1-10) 3.0     (0-11) 0.072
Diameter GSV upper thigh(mm) 6.3 (SD 2.1)    (2.4-15.4) 5.6 (SD 1.8)    (2.3-11.9) 0.009
Diameter GSV mid thigh(mm) 5.8 (SD 1.9)    (1.5-13.6) 5.1 (SD 1.5)    (2.3-10.4) 0.005
Diameter GSV low thigh(mm) 5.3 (SD 2.1)    (1.2-12.8) 4.9 (SD 1.5)    (2.2-10.3) 0.10
AASV reflux 16      (15.2%) 12      (10.0%) 0.24
Distal GSV reflux 93      (89%) 92      (76.7%) 0.02
Volume of injected foam(ml) 5.2 (SD 2.7)    (0-20) 5.0 (SD 2.0)    (0-10) 0.62
Table 2. results from univariate and multivariate Cox regression analyses.Hazard ratios (Hr)  represent relative risk 
of recurrence.
  Univariate analyses Multivariate analyses
HR (95% CI) p-value HR (95% CI) p-value
Age 1.006 (0.992-1.02) 0.408
Gender (female vs male) 1.073 (0.693-1.664) 0.751
Upperthigh diameter (mm) 1.011 (1.002-1.019) 0.016
Midthigh diameter (mm) 1.014 (1.004-1.024) 0.007 1.012 (1.002-1.022) 0.022
Lowthigh diameter (mm) 1.009 (0.999-1.019) 0.074
CEAP classification
 (C4-5 vs C2-3) 
1.595 (0.936-2.716) 0.086 1.509 (0.882-2.583) 0.134
VCSS 1.062 (0.972-1.160) 0.186
AASV reflux 1.215 (0.714-2.069) 0.473
Distal GSV reflux 1.922 (1.053-3.508) 0.033 1.882 (1.029-3.443) 0.040
Foam Volume (cc) 1.009 (0.935-1.090) 0.811
only variables with p-values<0.15 were included in the multivariate regression analysis
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GSV reflux, presence of AASV reflux and VCSS at baseline are shown in Table 2. Diameter 
of the GSV at all three levels (upper thigh, mid thigh and lower thigh), presence of reflux 
in the distal GSV lower leg and CEAP classification (CEAP 4-5 compared to CEAP 2-3) were 
associated with increased 2-year risk of recurrent reflux. Diameter at mid thigh level showed 
the strongest association with risk of treatment failure and was entered into a multivariate 
Cox regression model together with presence of distal GSV reflux and CEAP classification. 
Diameters at the other levels were not entered in the multivariate model, because strong 
correlation between potential predictors can cause predictors to compete and make 
the selection of relevant predictors arbitrary. results derived from the multivariate Cox 
regression model are also presented in table 2. After mutual adjustment the diameter of the 
thigh as well as reflux of the distal GSV and C4-C5 remained predictive.
Patients were classified into subgroups according to presence and absence of mid thigh 
diameter >6mm and/or distal reflux (Table 3). Due to the low number of patients with 
CEAP 4-5 (n=24) distinction between patients with CEAP 2-3 versus CEAP 4-5 within these 
subgroups would result in estimates with wide 95% CI and  therefore these estimates are 
not presented. The use of a cut-off point of 6mm for mid thigh diameter was based on 
the study of Myers et al10. The observed 2-year cumulative probabilities of recurrence free 
survival within the subgroups were calculated using Kaplan Meier survival analysis. In the 
subgroup with presence of reflux in distal GSV in combination with a diameter >6mm, the 
observed 2-year cumulative probability of saphenous reflux recurrence after one session 
was 63.9% (95% CI: 51.9%-75.8%). In the subgroup with only one risk factor present  the 
observed probability was 46.5% (95% CI: 38.2%-55.8%). When both risk factors were absent, 
the observed probability was 27.0% (95% CI: 15.4%-45.5%) (Table 3). 
Table 3. observed 2-year cumulative probability of recurrence (95% confidence intervals) according to patient 
characteristics.
Number of 
patients
Observed cumulative 
probability  of
recurrence free survival
Observed cumulative 
probability  of 
recurrence
Mid thigh diameter< 6 mmm 154 58.0% (46.6%-65.4%) 42.0 % (34.6%-50.4%)
Mid thigh diameter ≥ 6 mmm  70 37.4% (25.8%-48.9%) 62.6% (51.2%-74.2%)
Distal GSV reflux absent  40 69.5% (52.5%-81.3%) 30.5% (18.6%-47.5%)
Distal GSV reflux  present 185 47.9 % (40.3%-55.1%) 52.1% (44.9%-59.6%)
Both risk factors absent  34 73.0 % (54.5%-85.0%) 27.0 % (15.4%-45.5%)
one risk factor present 126 53.5% (44.2%-61.9%) 46.5% (38.2%-55.8%)
Both risk factors present  64 36.1% (24.2%-48.2%) 63.9% (51.9%-75.8%)
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Discussion
The demand for minimally invasive techniques such as UGFS in the treatment of GSV has 
considerably increased over the last few years, so defining prognostic factors for recurrence 
after treatment could potentially be important in a selection of those patients who might 
benefit from UGFS treatment and refine treatment. This study showed that a larger diameter 
of the GSV and presence of distal GSV reflux at baseline are predictive of a higher 2-year risk 
of recurrence.
In the present study we report a higher percentage of reflux recurrence than in the original 
trial. We performed a primary failure analysis and considered every recurrence of reflux 
as a failure irrespective of success after retreatment whereas in the original randomised 
controlled trial the initial recurrence of reflux was not counted as a treatment failure 
(secondary failure analysis).
Two previous studies reported on covariates affecting treatment success of UGFS. In the 
study of Myers et al. a Cox regression analysis showed a worse primary success rate for 
patients less than 40 years old, small compared to great saphenous veins, veins greater than 
6mm diameter compared to veins smaller than 5mm, patients treated with liquid compared 
to UGFS and patients treated with volumes of sclerosant less than 12 ml compared to 
volumes greater than 12ml10. In the study of Gonzalez-Zeh a 90% treatment success of 
UGFS was observed for veins with a diameter <6.5mm11. The finding that GSVs with a larger 
diameter have a higher probability of failure is in line with these results from literature. The 
findings provide evidence that in these patients there might be an indication for alternative 
options such as, endovenous laser ablation (ELVA), radiofrequency ablation (rFA) or surgery.
Another important finding in this study is that distal GSV and a higher C of the CEAP 
classification is a predictor of recurrent reflux. It seems that a more extended stage of 
varicose vein disease is associated with a higher risk of recurrence. In our study recurrence 
was defined as reflux in the proximal GSV, which was the treated segment in this study. We 
cannot fully explain the finding that a refluxing distal GSV at baseline is associated with 
more recurrences in the proximal GSV. Currently, little is known about the mechanism of 
recanalisation after UGFS. A hypothesis might be that just treating reflux in the proximal 
GSV may not result in sufficient haemodynamic modifications to prevent a recurrence 
(recanalisation)12. Another hypothesis is that, in the presence of distal GSV reflux and diameter 
>6mm, the higher reflux volume might prevent adequate damage of the endothelial cells 
and effective thrombosis and formation of a fibrous cord afterwards. Vascular fibrosis and 
obliteration only occur after irreversible destruction of the endothelial and subendothelial 
cellular layers of the treated vein segment13.
Ch
ap
te
r 7
 Predictors of recurrence of GSV reflux after UGFS 95
The question that arises is whether a refluxing GSV with extended reflux below the knee 
needs to be treated both proximally and distally in one session. According to Kostas et al. 
the appropriate length of stripping should be based on the extent of reflux seen by duplex. 
They found significantly more recurrences in the tibial area with restricted GSV stripping 
than in limbs with total GSV stripping14. Theivacumar et al. did show similar outcomes 
for endovenous laser ablation (EVLA) after 12 weeks15. The results in this study may also 
provide arguments to start ablation from the lowest point of axial vein reflux. Leaving distal 
reflux untreated may promote further reflux that can be essential for developing signs 
and symptoms of CVD16(16). An advantage of UGFS might be that if the below knee GSV 
is concomitantly treated the risk of nerve injury is probable less than with thermal ablation 
and surgery. An alternative option, is a more conservative way of approaching patients with 
a more extended varicose venous reservoir and  to investigate if ablation of the proximal 
trunk has resulted in an absence of reflux in the distal GSV. 
This study had some limitations. First, in this study no distinction can be made between 
predictors of  persistent reflux or early/mid term recurrences as the first moment of follow-
up after treatment was at 3 months. Therefore, it was not possible to evaluate whether 
mechanisms underlying very early failures may be different  from those underlying later 
failures. Second, in the original rCT we primarily focussed on the treatment of the proximal 
trunk which may have resulted in a relatively high percentage of recurrent saphenous reflux. 
In conclusion, this prospective study has shown that UGFS treatment for the proximal GSV 
is less effective for patients with a large vein, a refluxing distal GSV and C4-C5 at baseline. 
As the results in the present study and other studies15,16 suggest that a more extended 
stage of varicose veins or untreated reflux is associated with a higher risk of recurrence and 
progression of CVD it may be preferable to treat all the refluxing veins in one session. The 
findings need to be validated in further prospective studies.
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In the treatment of varicose veins, surgery is still the standard treatment in many hospitals, 
but in the last decades there has been an impressive change in management of patients 
with varicose veins. A trend can be observed towards treating varicose veins by less invasive 
techniques such as foamsclerotherapy and thermal endovenous ablation techniques1,2. 
These minimally invasive techniques are considered attractive alternatives because of 
their efficacy in eliminating venous reflux without the side effects of an invasive surgical 
technique1,3. In combination with the high success rates this technique is attractive for 
physicians and patients are satisfied by the procedures and the short recovery period4-6. 
Moreover, minimally invasive techniques can be performed under local anaesthesia instead 
of general anaesthesia and are associated with lower treatment costs4. Such cost savings are 
expected to have considerable impact on national health care budgets, because prevalence 
of varicose veins is high7. However, new and promising treatments need critical appraisal 
with regard to effectiveness, evidence is required that cost savings can be achieved without 
compromising health and prognosis of individual patients. 
This thesis addresses cost-effectiveness of foam sclerotherapy which was evaluated in a 
non-inferiority randomized controlled trial performed in three Dutch hospitals. The results 
show that replacing surgery by UGFS would result in a cost reduction of more than €1000 
per patient, whereas UGFS treatment is not inferior to surgery when presence of reflux in 
combination with symptoms is considered as primary outcome measure. In this scenario, 
it is assumed that only patients with recurrent reflux associated with venous symptoms 
are candidates for re-treatment sessions of UGFS. In the trial, 40 of 230 patients (17.4%) 
patients had a repeat session and despite the need for these additional treatments UGFS 
is still cheaper than surgery because of the lower costs of the procedure. The finding that 
27 patients assigned to surgery withdrew from the study before the start of treatment 
compared to 3 patients assigned to UGFS supports the notion that patients tend to prefer 
less invasive treatment to surgery.  
The conclusion regarding non-inferiority of UGFS to surgery largely depends on the 
definition of success, because the proportion of patients with recurrent reflux irrespective 
of presence of symptoms was considerably higher than the proportion of patients with 
both reflux and symptoms. Thus, if success is defined as obliteration of reflux, the 2-year 
probability of failure was significantly lower in patients treated by surgery than in patients 
treated by UGFS (21% versus 35%) and non-inferiority of UGFS could no longer be excluded. 
These results are in line with the findings in another recently published randomized trial by 
rasmussen et al8, that compared UGFS as well as endovenous laser ablation (EVLA) and radio 
frequency ablation (rFA) with surgical stripping. With regard to elimination of GSV reflux, 
UGFS was significantly less effective than the other methods. At one year after treatment 
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16.3% of GSVs treated with foam were refluxing versus 5.8% after EVLA, 4.8% after rFA and 
4.8% after surgery. Symptom severity and quality of life scores improved significantly in all 
treatment groups with no differences between groups. The mean costs were lowest in the 
UGFS group. 
These findings raise the question how success after treatment for varicosity needs to be 
defined. Should treatment success be defined in terms of anatomical results, i,e abolishing 
of reflux, or should presence of symptoms also be taken into account? In most studies 
outcome after varicose veins treatment is defined as the abolishing of reflux or occlusion of 
the vein in case of endovenous ablation techniques8-10. But in daily practice, indication for 
re-treatment is often guided by persistence of symptoms11. If patients do not present with 
subjective complaints, there is often no reason for referral to examination of the treated 
vein by ultrasound or further treatment. The choice for presence of reflux in combination 
with presence of symptoms as primary outcome measure is therefore consistent with a 
pragmatic approach and daily practice.
However, it may be argued that persistence or recurrence of reflux should be the focus 
of interest, because it may be a better indicator of prognosis. From a pathophysiological 
viewpoint recurrent reflux puts the patients at risk for further deterioration of the venous 
system12. Untreated reflux may lead to progression of CVI with an increased risk of skin 
changes and ulceration. The increased risk of future complications would support an 
approach towards also treating reflux in patients who do not have symptoms. A problem 
is that the evidence base for such an approach is limited. Most patients with symptomatic 
primary disease are treated early after presentation and therefore the rate of progression 
from C2 varicose veins to skin changes and ulceration is not known13. Until now, as neither 
the cause of venous disease nor the disease progression are fully understood, the discussion 
about the optimal treatment outcome remains to be decided.  
An outcome addressing both anatomical success and symptom relief fits in with a growing 
interest for reporting effectiveness of medical interventions in terms of subjective measures 
in addition to objective measures. Patient-reported outcomes such as relief of symptoms 
and improvement in health related quality of life are considered to be more relevant to 
patients than outcomes that merely reflect anatomic and morphological features14. Several 
intervention studies have demonstrated that ablation of incompetent superficial veins 
leads to substantial symptom relief and superior quality of life15,16. The rising interest in 
measuring subjective health outcomes has led to development of questionnaires that 
measure symptom and quality of life scores. But validity of these questionnaires may be 
compromised by poor correlation between venous symptoms and presence of CVI and 
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reflux11,17. The finding that after UGFS many patients with recurrent reflux did not report 
any symptoms raised the question to what extent symptoms that are commonly attributed 
to a venous cause can discriminate between patients with and without reflux. This question 
prompted a study which compared the prevalence of venous symptoms between a group of 
patients with CVI and reflux and a group of patients with other diseases with leg symptoms, 
such as arthrosis, peripheral arterial disease, or spinal disc herniation. In this study using 
a validated questionnaire on symptom frequency, only small differences in prevalence of 
reported “venous” symptoms were observed between the compared groups. It was shown 
that patients with CVI were more likely to experience symptoms at the end of the day, but 
based on all other items CVI could not obviously be differentiated from other leg diseases. 
There seems need for improvement of questionnaires on symptom scores, including 
specific questions about circumstances that elicit and exacerbate or alleviate symptoms. 
Questionnaires could also benefit from more detailed descriptions of sensations. From daily 
practice we know, that patients with venous complaints describe a pain in the lower legs, 
they feel the sensation of creeping ants on the skin and they feel the need to elevate their 
legs whenever possible. 
UGFS has been performed for some decades now and seems to be a safe therapy. The 
main concern for every physician is the occurrence of the most serious adverse event: a 
thromboembolic complication. The risk of a thromboembolic event after treatment with 
UGFS is reported to be approximately 1%18. The results in this thesis support the reported 
low risk of thromboembolic complications. UGFS initiates coagulation pathways, but there is 
no evidence that this activation results in a hypercoagulable state in peripheral blood after 
treatment, at least in patients without apparent thrombophilic defects. Little is known about 
the use of UGFS in patients with coagulation disorders such as Factor V Leiden and protein C 
or S deficiency. Future (in vitro) studies may be desirable to investigate whether use of UGFS 
in patients with coagulation disorders augment the risk on thromboembolic events.
The question was also addressed how the treatment with UGFS and the indications for 
the use of UGFS can be optimized. UGFS for the incompetent GSV is effective in about 2 
of 3 patients. The probability of persistent success decreases in the presence of a large 
diameter, refluxing distal GSV or C4-C5 at baseline. GSVs larger than 6mm are more prone 
for treatment failures after 2 years and other endovenous thermal ablation techniques or 
varicose vein surgery may thus be better treatment options in larger veins. Furthermore, the 
effectiveness of foam may be improved if GSVs are only treated when refluxing distal GSV is 
absent. An alternative option is to treat the whole length of the refluxing GSV. This approach 
would be in line with the hypothesis that leaving untreated reflux may promote further 
reflux. By optimizing selection and treatment, success rates may increase. 
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UGFS seems to be a an appropriate method for the treatment of primary GSV incompetence 
if these veins are smaller than 6mm and in the absence of distal GSV reflux. In addition 
UGFS is a good alternative for non saphenous veins. one of the advantages of UGFS is that 
it progresses easily into the venous network, whatever its anatomical characteristics are. 
This feature makes it possible to treat all kinds of complex varicose veins. Especially for 
the tortuous and recurrent veins after surgery or thermal ablation UGFS is a good option. 
Small veins with a diameter less than 4 mm are easily accessible for foam sclerotherapy 
because a needle or intravenous cannula is used. In addition, UGFS can be used for those 
veins with segmental recanalizations after endovenous laser or radiofrequency, and also 
after previous treatment with foam. There is less risk of nerve damage with UGFS than with 
thermal ablation, but the risk on thrombophlebitis and hyperpigmentation might be higher 
after UGFS. of the endovenous ablation techniques UGFS is the least invasive and the direct 
treatment costs and treatment time are lowest.
Based on the data in this thesis we can conclude that UGFS is a safe and cost-effective 
minimally invasive approach in treating GSV varicose veins. In the era of new treatment 
methods guided by ultrasound UGFS has found its place. Both, physicians and patients 
appreciate the minimal invasiveness of the technique. The indications for UGFS have been 
sharpened. The optimal way for evaluation of effectiveness of alternative treatments of 
varicose veins should take into account both patients complaints and anatomical findings. 
The choice of treatment method should be made on an individual base and therefore the 
physician should be able to apply different techniques. It remains an important field of 
discussion which patients should be treated and how we should measure the success of 
the treatment. Use of UGFS to achieve the relief of symptoms in patients suffering from 
varicose veins combines the advantages of minimal invasiveness and cost reduction. For 
this reason, UGFS can be recommended as treatment that can replace more expensive and 
more invasive techniques.  
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The fast introduction of UGFS in many medical centres prompted the need for evaluation of 
the cost-effectiveness and safety of this technique when compared to surgery. This thesis 
addresses the results of a large multi-centre randomized controlled trial that was initiated to 
evaluate non-inferiority of UGFS compared to stripping with ligation and the volume of cost 
savings that could be achieved by implementation of UGFS in clinical practice. Secondary 
objectives were to explore safety in terms of the effect of foam injection on coagulability of 
bloods and to identify predictors of treatment success after foam sclerotherapy.  
Chapter 1 describes the aims of this thesis. As an introduction it provides a short overview of 
prevalence, pathogenesis and diagnosis of CVI and reviews the development of minimally 
invasive interventions aimed at obliterating reflux in veins. 
Chapter 2 presents a Dutch foam consensus based on literature and clinical experience 
of various medical specialists such as dermatologists, vascular surgeons and radiologists, 
which was organized to achieve standardization of UGFS. Important recommendations 
concerned the preparation of foam (concentration of sclerosant and volume of foam), 
location of injection and duration of compression therapy after treatment. The foam that is 
used is a mixture of 1 ml sclerosant (polidocanol) and 4ml of  air (1:5). regarding long term 
results in achieving occlusion of the treated vein it could been shown that 1% polidocanol is 
as effective as 3% polidocanol. Therefore it was decided to use 1% polidocanol. A maximum 
volume of 10cc for the GSV and 5cc for the SSV is recommended. A slow injection is 
preferred and the treatment is considered to be successful when venospasm is achieved. 
The best location to insert a varicose vein with a needle or a18-Fr intravenous cannula is just 
above the knee in case of a great saphenous vein (GSV) or as distal as possible when a small 
saphenous vein (SSV) is treated. After treatment, compression therapy during a period of 4 
weeks with a foam pad over the treated area for 1 week was recommended. 
Chapter 3 presents the results of a multicentre randomized clinical trial that was 
designed with the underlying hypothesis that UGFS is not inferior to surgery in treating 
the incompetent great saphenous vein (GSV) when re-treatment sessions are allowed. 
Patients with one or more venous symptoms in combination with incompetence of the 
saphenofemoral junction and GSV with a reflux time >0.5s (measured over a distance of at 
least 20 cm in the upper leg) were included at three different hospitals in the south of the 
Netherlands. From october 2005 to December 2007, a total of 460 patients were enrolled and 
eventually 430 patients underwent the assigned treatment. Withdrawal after randomization 
and before start of treatment occurred mainly in the surgery group. The primary outcome 
measure of this study was the cumulative probability of recurrent varicose veins at 2 years 
after treatment. recurrence was defined as reflux combined with venous symptoms and 
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the non-inferiority margin was set at 10%. Secondary outcomes were presence of recurrent 
reflux (irrespective of symptoms), reduction of symptoms, health-related quality of life (EQ-
5D), adverse events and direct hospital costs. outcomes were evaluated at 3 months, 1 year 
and two years post treatment. 
The probability of recurrence in the UGFS group was 11.3% compared with 9% in the surgery 
group after two years with a difference of 2.3% (95% CI: -4.3 to 8.1%). The proportion of 
patients with reflux irrespective of venous symptoms was significantly higher after UGFS 
than after surgery: 35% and 21%, respectively. The difference was 14.0 % (95% CI: 4.4 to 
22.3%). Mean changes in Venous Clinical Severity Score (VCSS) and EQ-5D utility score and 
symptom relief did not differ significantly between treatment groups. The most frequently 
observed adverse events after GFS were thrombophlebitis and hyperpigmentation (7.4% 
and 5.6%), parasthesia was most often observed in the surgery group (3%). one deep 
venous thrombosis and one pulmonary embolism occurred in the UGFS group. Cost 
analysis showed mean hospital costs per patient of €774 for UGFS and €1824 for surgery. 
In conclusion UGFS is not inferior to surgery in treating GSV reflux associated with venous 
symptoms and can lead to cost savings of about €1000 per patient.  
Chapter 4 compares the frequency of symptoms that are commonly attributed to venous 
disease between 76 patients with CVI and reflux and 74 patients with other leg disease such 
as arthrosis, spinal disc herniation and peripheral arterial disease (25 arthrosis, 23 spinal disc 
herniation, 26 peripheral arterial disease). The VEINES-QoL/Sym questionnaire was used to 
measure symptom frequency and severity. This questionnaire includes nine items on venous 
symptoms (heavy legs, aching legs, swelling, night cramps, heat or burning sensation, 
restless legs, throbbing, itching, tingling sensation) which are rated on a five-point scale of 
frequency (1=every day, 2=several times a week, 3=about once a week, 4=less than once a 
week, 5=never). Higher proportions in the CVI group were observed for six symptoms, but 
between-group differences were small and non-significant. Severity of CVI as classified by 
the CEAP classification was not associated with higher proportions of patients reporting 
symptoms except for swelling and itching. The largest difference between the CVD and non-
CVI group was observed for time of the day at which symptoms were most intense; patients 
with CVI were more likely to experience symptoms at the end of the day. These results 
suggest that these symptoms may be less specific for patients with refluxing veins than is 
usually assumed. This finding implies that venous symptom questionnaires that address 
only type and frequency of these symptoms may not be specific enough to identify patients 
with CVI and reflux. There may be need for improvement of venous symptom questionnaires 
with more attention for circumstances that exacerbate and alleviate symptoms. 
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Chapter 5 illustrates, based on a case report, an event of a deep venous thrombosis 
following a superficial thrombophlebitis. A few days after UGFS of the distal GSV a female 
patient developed a superficial thrombophlebitis of the venous dorsal arch which was 
treated with non-steroidal anti-inflammatory drugs and compression hosiery. Six weeks 
after weekly follow-up with color duplex sonography, a deep venous thrombosis of the 
popliteal vein was revealed. oral anticoagulant therapy was started. The occurrence of 
a superﬁcial thrombophlebitis that is not located close to the treated vein should be an 
indication for regular follow-up examinations to prevent missing the occurrence of disease 
progression and a possible involvement of the deep venous system.
Chapter 6 describes the results of a study with the objective to evaluate whether UGFS 
induces changes in coagulation parameters, which when compared with baseline may 
be indicative of an increased risk of thrombotic events. Two other studies have previously 
reported on in vivo effects of UGFS, but this is the first the study which uses Calibrated 
Automated Thrombography (CAT). A thrombogram shows thrombin generation over time 
and relevant CAT parameters are the endogenous thrombin potential (ETP), lag time, peak 
height (Peak). Lag time is defined as the time to initial thrombin formation in minutes, 
ETP is the area-under-the-curve representing the presence of thrombin in time and 
peak height represents the maximal concentration of thrombin formed in plasma in nM. 
These CAT parameters and more traditional parameters such as thrombin anti-thrombin 
complexes (TAT), d-dimers, fibrinogen, Von Willebrand (vWf Ag) factor and platelet derived 
microparticles (MIPA’s) were measured in eight patients before and after treatment with 
UGFS. Significant changes over time were observed for fibrinogen, D-dimers, vWfAg and 
TAT complexes and these changes are suggestive of initiation of coagulation pathways. 
An interesting finding was that ETP and peak height decreased over time, which may 
be suggestive of a compensatory mechanism. It was concluded that foam sclerotherapy 
initiates coagulation pathways, but there is no evidence that this activation results in an 
increased thrombosis risk. 
The aim of Chapter 7 was to investigate which clinical characteristics at baseline are 
predictive variables for recurrence of GSV reflux after one single session of ultrasound-
guided foamsclerotherapy (UGFS).  Data of patients treated for GSV incompetence with 
UGFS were derived from the randomized clinical trial described in chapter 3. A total of 225 
patients were available for analysis. Treatment after one single session was successful in 120 
patients and recurrence of reflux was observed in 105 patients within 2 years of follow-up. 
Baseline characteristics which were considered as potential predictors of treatment success 
were gender, age, clinical class of CEAP classification, diameter of GSV, amount of injected 
foam, presence of distal GSV reflux, presence of AASV reflux and VCSS. Larger GSV diameters 
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in the thigh, reflux of the distal GSV and a higher C of the CEAP classification (CEAP 4-5 
compared to CEAP 2-3) were associated with increased 2-year cumulative probability of 
failure. The results provide arguments that a refluxing GSV with extended reflux below 
the knee needs to be treated both proximally and distally in one session. Leaving distal 
reflux untreated may promote further reflux that can be essential for developing signs and 
symptoms of CVI. Furthermore, we can conclude that UGFS treatment for the proximal GSV 
is less effective for patients with a vein >6mm and might not be the first choice treatment 
for these patients. 

Chapter 10
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De snelle introductie van foamechosclerose voor behandeling van chronisch veneuze 
insufficiëntie (CVI) in vele medische centra noodzaakt evaluatie van de kosteneffectiviteit 
en veiligheid van deze techniek in vergelijking met chirurgie. Dit proefschrift behandelt 
de resultaten van een groot multicentre gerandomiseerd onderzoek dat geïnitieerd werd 
om aan te tonen dat foamechosclerose niet minder effectief is dan crossectomie en te 
bepalen welke  kostenreductie haalbaar is door de foam behandeling toe te passen in 
de klinische praktijk. Daarnaast behandelt dit proefschrift andere relevante aspecten van 
foamechosclerose zoals het effect van foam injectie op de bloedstolling en identificatie 
van patiënt- en ziektekenmerken die de kans op succesvolle verwijdering van reflux door 
foamechosclerose vergroten.
Hoofdstuk 1 beschrijft de doelstellingen van dit proefschrift. Ter introductie biedt het 
een overzicht van de prevalentie, pathogenese en diagnose van CVI en bespreekt het de 
opkomst en de ontwikkeling van minimaal invasieve interventies gericht op het verwijderen 
van reflux van in venen.
Hoofdstuk 2 behandelt een Nederlandse foam consensus,  die werd georganiseerd om 
standaardisatie te bereiken in de foam behandeling en gebaseerd is op de klinische expertise 
van diverse medisch specialisten zoals dermatologen, vaatchirurgen en radiologen. 
Belangrijke aspecten betreffen de bereiding van foam (concentratie sclerosans en volume 
van foam), locatie van de injectie en duur van de compressie therapie na de behandeling. 
De foam die wordt gebruikt is een mengsel van 1 ml sclerosant (polidocanol) en 4ml lucht 
(1:5). Gebruik van 1% polidocanol wordt geadviseerd op basis van vergelijkbare  lange 
termijn resultaten van 1% en 3% polidocanol in het behalen van occlusie van de behandelde 
vene. Een maximaal volume van 10cc voor de vena saphena magna (VSM) en 5cc voor de 
vena saphena parva (VSP) wordt aanbevolen. Een langzame injectie is te prefereren en 
de behandeling wordt als succesvol beschouwd als venospasme wordt bereikt. De beste 
locatie om een spatader met een naald of een 18-gauge venflon aan te prikken is net boven 
de knie in het geval van de VSM of zo distaal mogelijk als de VSP wordt behandeld. Na 
behandeling wordt compressie therapie gedurende 4  weken met een foam pad over het 
behandelde gebied voor 1 week aanbevolen.
Hoofdstuk 3 beschrijft de resultaten van een multicentre gerandomiseerd klinisch 
onderzoek dat is opgezet met de onderliggende hypothese dat foamechosclerose niet 
inferieur is aan chirurgie voor de behandeling van de insufficiënte vena saphena magna 
(VSM) als daarnaast ook herbehandelingen zijn toegestaan. Patiënten met één of meer 
veneuze symptomen in combinatie met insufficiëntie van de saphenofemorale crosse 
en VSM met een reflux tijd van >0.5s (gemeten over een afstand van minstens 20 cm in 
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het bovenbeen) werden geïncludeerd in drie ziekenhuizen in Zuid Nederland. Tussen 
oktober 2005 en december 2007, werden in totaal 460 patiënten geïncludeerd. Uiteindelijk 
ondergingen 430 patiënten de toegewezen behandeling. Terugtrekking na randomisatie 
en voor de start van de behandeling deed zich met name voor in de chirurgie groep. De 
primaire uitkomstmaat van deze studie was de cumulatieve kans op recidief varicositas 
binnen 2 jaar na behandeling. Een recidief werd gedefinieerd als reflux gecombineerd met 
de aanwezigheid van veneuze symptomen. Een  toename van maximaal 10% recidiefkans 
werd als acceptabel beschouwd (non-inferiority marge van 10%). Secundaire uitkomstmaten 
waren de aanwezigheid van recidief reflux (ongeacht de aanwezigheid van veneuze 
symptomen), vermindering van symptomen, gezondheid-gerelateerde kwaliteit van leven 
(EQ-5D), bijwerkingen en directe ziekenhuis kosten. resultaten werden geëvalueerd bij 3 
maanden, 1 jaar en twee jaar na behandeling.
De kans op recidief in de foamechosclerose groep was 11,3% vergeleken met 9% in de 
chirurgie groep na twee jaar met een verschil van 2.3% (95% CI: -4.3 to 8.1%). Het aantal 
patiënten met reflux ongeacht de aanwezigheid van veneuze symptomen was significant 
hoger na foamechosclerose dan na chirurgie: respectievelijk 35% en 21%. De gemiddelde 
verandering in de VCSS en EQ-5D utiliteit-score en symptoom verlichting verschilden 
niet significant tussen de twee behandelde groepen. De meest frequent geobserveerde 
negatieve effecten na foamechosclerose waren thromboflebitis en hyperpigmentatie (7.4% 
en 5.6%), paresthesie werd het meest frequent geobserveerd in de chirurgie groep (3%). 
Eén diep veneuze trombose en één longembolie traden op in de foamechosclerose groep. 
Kostenanalyse toonde aan dat de gemiddelde ziekenhuis kosten per patiënt €774 waren 
voor foamechosclerose en €1824 voor chirurgie. Concluderend kan gezegd worden dat 
UGFS niet inferieur is aan chirurgie voor de behandeling van VSM reflux in patienten met 
veneuze symptomen en een kostenbesparing van circa  €1000 per patiënt kan opleveren.  
Hoofdstuk 4 vergelijkt de frequentie van symptomen die vaak worden toegeschreven aan 
veneuze ziekte tussen 76 patiënten met CVI en reflux en 74 patiënten met andere beenziektes 
zoals artrose, wervel hernia en perifere arteriële ziekte (25 artrose, 23 wervelhernia, 26 
perifere arteriële ziekte). The VEINES-QoL/Sym-vragenlijst werd gebruikt om symptoom 
frequentie en ernst van symptomen te meten. Deze vragenlijst bevat 9 items van veneuze 
symptomen (zware benen, pijnlijke benen, zwelling, nachtelijke krampen, kloppend, 
jeukend, tintelend gevoel) die worden gescoord op een 5-puntsschaal van frequentie 
(1=elke dag, 2=meerdere malen per week, 3=ongeveer eenmaal per week, 4=minder dan 
eenmaal per week 5=nooit). Hogere proporties in de CVI groep werden gevonden voor zes 
symptomen, maar de verschillen tussen de groepen waren klein en niet significant. Behalve 
voor de symptomen zwelling en jeuk, was de ernst van CVI  volgens  de CEAP classificatie 
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niet geassocieerd met hogere proporties  patiënten die symptomen rapporteerden. Het 
grootste verschil tussen de CVI en niet-CVI groep werd geobserveerd voor het tijdstip van 
de dag waarop de symptomen het meest intens waren; patiënten met CVI hebben meer 
kans op het ervaren van klachten aan het einde van de dag. Deze resultaten suggereren 
dat deze symptomen mogelijk minder specifiek zijn voor patiënten met veneuze reflux 
dan over het algemeen wordt aangenomen. Vragenlijsten voor veneuze symptomen die 
alleen het type en de frequentie van de symptomen betreffen zijn dus wellicht niet specifiek 
genoeg om patiënten met CVI en reflux te identificeren. Dit impliceert dat er behoefte is 
aan een verbetering van vragenlijsten met meer aandacht voor omstandigheden die de 
klachten verergeren of verlichten. 
Hoofdstuk 5 illustreert, gebaseerd op een case report, het optreden van een diep veneuze 
trombose na een oppervlakkige tromboflebitis. Een paar dagen na foamechosclerose van 
de distale VSM ontwikkelde een vrouwelijke patiënt een oppervlakkige tromboflebitis van 
de arcus venosum dorsalis pedis. Deze werd behandeld met ontstekingsremmers (NSAID’s) 
en steunkousen. Zes weken na een wekelijkse follow-up met veneus duplexonderzoek, 
werd een diepe veneuze trombose van de vena poplitea vastgesteld. orale anticoagulatie 
therapie werd gestart. Een oppervlakkige thromboflebitis die niet in de buurt zit van de 
behandelde vene is een indicatie ivoor frequent follow-up onderzoek. Dit om te voorkomen 
dat ziekte progressie en de mogelijke betrokkenheid van het diep veneuze systeem worden 
gemist.
Hoofdstuk 6 beschrijft de resultaten van een studie met als doel te beoordelen of 
foamechosclerose veranderingen teweeg brengt in coagulatie parameters, die indicatief 
zijn voor een verhoogd risico op trombotische aandoeningen. Twee andere studies 
hebben eerder gerapporteerd over in vivo effecten van foamechosclerose, maar dit is de 
eerste studie die gebruik maakt van gekalibreerde geautomatiseerde trombografie (CAT). 
Een thrombogram toont thrombine generatie over de tijd en relevante CAT parameters 
zijn de endogeneous thrombin potential (ETP), lag time en peak height. Lag time wordt 
gedefinieerd als initiële tijd tot de formatie van thrombine, ETP is het gebied onder de curve 
dat de aanwezigheid van thrombine in de tijd aangeeft, peak height vertegenwoordigt 
de maximale concentratie van thrombine die wordt gevormd in plasma.  Deze  CAT 
parameters en ook andere parameters zoals  trombine anti-trombine complexen (TAT), 
d-dimeren, fibrinogeen, de Von Willebrand (vWf Ag) factor en van bloedplaatjes afgeleide 
micropartikels (MIPA’s) werden gemeten in acht patiënten voor  en na behandeling met 
foamechosclerose. Significante veranderingen over de tijd werden geobserveerd voor 
fibrinogeen, d-dimeren, vWfAg en TAT complexen en suggereren de initiatie van de 
stollingscascade. Een interessante bevinding is dat de CAT parameters ETP en peak height 
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juist daalden wat suggestief kan zijn voor een compenserend mechanisme. Deze resultaten 
tonen aan dat foamechosclerse de stollingscascade initieert, maar er is geen aanwijzing dat 
deze activatie resulteert in een toegenomen risico op trombose.
Het doel van Hoofdstuk 7 is om na te gaan welke klinische karakteristieken voorspellend 
zijn voor recidief reflux van de VSM na een enkele foamechosclerose sessie. De hiervoor 
benodigde gegevens waren afkomstig uit de gerandomiseerde trial die in hoofdstuk 3 wordt 
beschreven. In totaal waren 225 patiënten beschikbaar voor analyse. Behandeling na één 
enkele sessie was succesvol bij 120 patiënten en een recidiverende reflux binnen 2 jaar na 
behandeling werd waargenomen in 105 patiënten. Baseline kenmerken die als potentiele 
voorspellers van een succesvolle behandeling werden meegenomen waren geslacht, 
leeftijd, C van de CEAP classificatie, diameter van de VSM, volume geïnjecteerde foam, 
aanwezigheid van distale VSM reflux, aanwezigheid van reflux in de  VSM accessoria anterior 
en VCSS. Grotere kans op recidief werd  geobserveerd voor patiënten met grotere GSV 
diameters in het dijbeen, reflux van de distale VSM en een hogere C van de CEAP classificatie 
(CEAP 4-5 versus CEAP 2-3). De resultaten wijzen erop  dat een VSM met reflux tot onder de 
knie zowel proximaal als distaal behandeld dient te worden in één sessie. Theoretisch kan 
het onbehandeld laten van distale reflux verdere reflux in de hand werken en leiden tot de 
ontwikkeling van verdere tekenen en symptomen van CVI.  Andere conclusies zijn dat de 
UGFS behandeling minder effectief is voor patiënten met een vene diameter van >6mm en 
daarom wellicht niet de voorkeursbehandeling is voor deze patiënten.
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Dankwoord
Het is zover, het is gelukt! De laatste pagina’s die nog gevuld gaan worden. Misschien wel 
de eerst en meest gelezen pagina’s van dit boekje. In ieder geval een tekst die niet heen en 
weer hoeft te worden gestuurd en vrij zal blijven van correcties en rode strepen. Aan een 
clichézin ontkom ik niet: “dit proefschrift had niet tot stand kunnen komen zonder de hulp van 
velen”, want zo is het!
Graag wil ik dan ook van de gelegenheid gebruik maken om iedereen die in directe of 
indirecte zin een bijdrage aan dit proefschrift heeft geleverd te bedanken: heel veel dank!
Een aantal van jullie wil ik in het bijzonder noemen.
In de eerste plaats wil ik alle patiënten bedanken die wilden meewerken aan de inhoud 
van dit proefschrift. Zonder jullie frequente polikliniek bezoeken en het invullen van de 
terugkerende, uitgebreide vragenlijsten was een groot deel van dit werk niet tot stand 
gekomen.
Professor Steijlen, heel veel dank voor het door u in mij gestelde vertrouwen. Ik ben blij 
dat u mij destijds als arts-onderzoeker heeft aangenomen. Twee jaar later bood u mij de 
mogelijkheid het onderzoek te combineren met de opleiding tot dermatoloog. Ik heb deze 
afwisseling als heel prettig ervaren, al was het soms lastig de aandacht goed te verdelen 
tussen de twee. Ik ben blij dat u achter mijn keuze stond en het vertrouwen had dat ik het 
zou afmaken. Dank voor de tijd en ruimte die u creëerde om deze combinatie te realiseren en 
ervoor te zorgen dat ik op de juiste momenten in de luwte bleef van de dagelijkse klinische 
werkzaamheden.
Lieve Anja, jij was het die mij de mogelijkheid bood om het Foamproject aan te gaan, de 
eerste stap naar dit proefschrift. Ik leerde van jou het flebologie vak, te spreken op grote 
congressen en prioriteiten te stellen. Je was altijd bereid mij thuis te ontvangen in de 
avonduren en brainstorm sessies te houden over de inhoud en opzet van het proefschrift. 
Deze avonden werden vaak vergezeld van een heerlijke maaltijd met in de eerste jaren een 
slapende Lucy naast de keukentafel. Hier vloeiden inspirerende ideeën uit voort die de basis 
vormen van dit proefschrift. Ik ben blij met de ruimte en vrijheid die je mij ook gaf om mijn 
eigen ideeën voor het onderzoek vorm te geven. Ik ben je hier heel dankbaar voor!
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Lieve Patty, ik ben je zo dankbaar voor al je betrokkenheid bij het schrijven van dit proefschrift. 
Zonder jou had dit proefschrift er niet gelegen! Ik kon altijd bij je binnenlopen en tot in de 
late uurtjes stond je mij te woord aan de telefoon of via de digitale weg. Jouw kritische en 
grootschalige input met betrekking tot het analyseren van data, opbouw van artikelen en 
het wetenschappelijke Engels zijn van enorme waarde voor dit proefschrift geweest. Ik heb 
heel veel van je geleerd. Daarnaast heb ik veel aan je steun gehad, je eindeloze geduld en het 
vertrouwen dat je uitsprak dat alle resultaten tot een promotie zouden leiden als ik het even 
niet meer zag zitten. Je hebt gelijk gehad. 
 
James Lawson, jij stond aan de wieg van mijn keuze voor een promotietraject binnen de 
flebologie. Met heel veel plezier heb ik een jaar bij jullie maatschap als ANIoS chirurgie in het 
Amstelland ziekenhuis gewerkt. Peter van Aken en jij wisten mijn eerste interesse voor de 
veneuze pathologie te wekken. Blij verrast was ik toen je belde en vertelde dat je voor 2 jaar 
op de afdeling dermatologie in Maastricht kwam werken. Veel dank voor de motiverende en 
prettige samenwerking, alle goede adviezen en flebologische artikelen over de mail. 
Lieve Heleen en Evelien, ik vind het heel fijn dat jullie straks op de dag van de verdediging 
achter mij willen staan als paranimfen. Ik ben heel blij met onze vriendschap. Dank voor alle 
steun en gezellige momenten zowel op de werkvloer als daarbuiten! Ik kan met alles altijd 
bij jullie terecht.
Heleen, je luisterend oor, humor en altijd relativerende woorden zijn voor mij heel waardevol. 
Ik ben blij dat we weer dichtbij elkaar zitten!
Evelien, je eigenheid en creativiteit zijn een enorme inspiratie. Jij wist mij op het juiste moment 
achter de computer vandaan te halen om een rondje te fietsten in het heuvellandschap of 
voor een wandeling door het Jekerdal en tussentijds te filosoferen over het leven. 
Monique de Laat, heel veel dank voor je tomeloze inzet tijdens het Foamproject. Je hebt 
honderden duplex onderzoeken uitgevoerd en deed dat steeds weer met hetzelfde 
enthousiasme. Met heel veel plezier kijk ik terug op onze fijne samenwerking en de 
maandelijkse autoritjes naar de periferie.
roeland Ceulen, jij maakte de eerste belangrijke stappen voor het Foamproject zodat 
het project vanaf de eerste dag goed van start kon gaan. Heel veel dank voor al je uitleg, 
meedenken en het wegwijs maken met het duplexonderzoek en de foamechosclerose.
rene Estourgie, Ed de Haan, Geert Willem Schurink, Joost van der Kley en Pierre van Neer 
veel dank voor al het werk dat jullie hebben verzet om tot het gevraagde aantal inclusies te 
komen. Het was altijd leuk om een dagdeel bij jullie in de periferie te werken.
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Professor Dirksen, Carmen, veel dank voor je waardevolle en wetenschappelijke bijdrage aan 
het Foamproject. Zonder jouw begeleiding van de kosteneffectiviteitsanalyse was het voor 
mij niet mogelijk geweest de “geld” bomen door het bos te zien. 
Professor ten Cate en rene van oerle, toen ik bij jullie kwam met het idee, om onderzoek te 
doen naar de effecten van foamechosclerose op stolling, waren jullie meteen bereid mee te 
denken en te werken. Veel dank voor jullie goede en laagdrempelige begeleiding.
Simone van der Velden, heel veel dank voor je hulp bij het stollingsonderzoek en je bijdrage 
aan de inhoud van hoofdstuk 4. Ik heb heel fijn met je samengewerkt! ook jouw promotie 
gaat zeker lukken!
Joep Veraart, dank voor je interesse in de vorderingen van het Foamproject en mijn 
proefschrift, je was altijd bereid mee te denken.
Jorge Frank, dank voor het kritisch meelezen tijdens het schrijven van de thromboflebitis-
DVT casus.
Alle dames van de polikliniek dank voor jullie hulp en ondersteuning tijdens de flebologie 
spreekuren. Marie-Paule in het bijzonder, jij zorgde ervoor dat de studie patiënten op tijd 
voor de follow-up werden opgeroepen.
Dames van het secretariaat, met jullie eerste groet en een praatje begon de dag altijd 
goed. Lieve Annelies en Ingrid, heel veel dank voor al jullie administratieve werk rond het 
Foamproject. Nicole en Petra dank voor jullie hulp, jullie waren altijd van alles op de hoogte! 
Annelies en Nicole, jullie hulp en ondersteuning bij de” laatste loodjes” was onmisbaar!
Lieve “oud” collega assistenten jullie hebben mijn tijd in Maastricht een extra dimensie 
gegeven. Jullie zorgden naast jullie collegialiteit en prettige samenwerking voor vele uurtjes 
ontspanning. Koffie drinken in het keukentje, biertjes in de Thembi, de etentjes thuis en 
uurtjes sporten. De jaarlijkse assistenten weekenden en skireisjes zijn onvergetelijk! Heel 
veel dank voor deze fantastische tijd! 
Promotie partners in crime; Klara, Charlene, Valerie, Sadhanna, Annemoon, Aimee en Annet. 
De uren op een uitgestorven oxford waren vaak productief en motiverend, maar ook heel 
gezellig. Het was fijn om met jullie de ups-and-downs van het promoveren te delen. 
Sharon en Lieke, dank voor alle steun en gezellige uurtjes samen!
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Ik wil alle stafleden van de dermatologie in Maastricht bedanken voor het opleiden en jullie 
interesse. ook mede namens jullie steun en medewerking was het voor mij mogelijk om het 
onderzoek te combineren met de opleiding.
Dermatologen uit het Medisch Centrum Haaglanden, ik ben blij dat ik met jullie samenwerk!
Lieve vrienden en (schoon) familie, ook al was het voor velen misschien niet altijd duidelijk 
waar ik veel van mijn tijd mee vulde de afgelopen jaren, jullie vriendschap, gezelligheid en 
steun was en is van wezenlijk belang. Dank voor alle fijne tijd en ontspanning ook al zat een 
groot aantal van jullie zo’n 200 km of nog meer verderop. Ik kijk uit naar de “promotieloze” 
tijd met jullie!
Lieve pap en mam, door jullie onvoorwaardelijke steun en liefde heb ik alle vrijheid gehad 
om mezelf te ontwikkelen en vormen tot wie ik ben. Jullie vaak wijze raad, positieve 
levenshouding en onuitgesproken woorden: “geniet van het leven, maar werk ook hard” zijn 
zeer waardevol geweest. Jullie hebben er altijd voor gezorgd dat er een warm thuis was en 
is, ik mag van geluk spreken met zulke ouders.
Mam, de cover is prachtig. Dit boekje is voor jullie!
Lieve Haroun en Marwan, ik ben heel blij met jullie als broers en onze goede band! Veel 
mooie herinneringen aan het samen groot worden en later de gezamenlijke weken in de 
Franse zon en winterse Alpen met aanhang. Ik hoop dat we dit nog lang mogen voortzetten. 
Haroun, we komen jullie snel opzoeken in Singapore!
Lieve Daniel, jij geeft mij zoveel liefde en energie! Jouw gedrevenheid in alles wat je doet 
werkt aanstekelijk. Je bent een heel belangrijke motor voor dit proefschrift geweest. Dank 
voor alles, maar vooral dat je bent wie je bent! 
Lieve Yara, jouw ontwapende lach en verwondering voor de kleine dingen om je heen doen 
mij beseffen wat echt belangrijk is in het leven. Ik verheug mij op een toekomst met vier en 
kijk uit naar weer meer tijd samen. Ik hou van jullie!
